Development of prototype gold nanoparticle-dased immunoassays for the detection of plasmodium falciparum hsp70 by Guirgis, Bassem Samy
American University in Cairo 
AUC Knowledge Fountain 
Theses and Dissertations 
2-1-2011 
Development of prototype gold nanoparticle-dased 
immunoassays for the detection of plasmodium falciparum 
hsp70 
Bassem Samy Guirgis 
Follow this and additional works at: https://fount.aucegypt.edu/etds 
Recommended Citation 
APA Citation 
Guirgis, B. (2011).Development of prototype gold nanoparticle-dased immunoassays for the detection of 
plasmodium falciparum hsp70 [Master’s thesis, the American University in Cairo]. AUC Knowledge 
Fountain. 
https://fount.aucegypt.edu/etds/1183 
MLA Citation 
Guirgis, Bassem Samy. Development of prototype gold nanoparticle-dased immunoassays for the 
detection of plasmodium falciparum hsp70. 2011. American University in Cairo, Master's thesis. AUC 
Knowledge Fountain. 
https://fount.aucegypt.edu/etds/1183 
This Thesis is brought to you for free and open access by AUC Knowledge Fountain. It has been accepted for 
inclusion in Theses and Dissertations by an authorized administrator of AUC Knowledge Fountain. For more 
information, please contact mark.muehlhaeusler@aucegypt.edu. 
The American University in Cairo 
 
School of Sciences and Engineering 
 
 
 
Development of Prototype Gold Nanoparticle-Based Immunoassays for the 
detection of Plasmodium falciparum Hsp70 
 
A Thesis Submitted to 
The Biotechnology Graduate Program 
 
in partial fulfilment of the requirements for 
the degree of Master of Science in Biotechnology 
 
By: Bassem Samy Guirgis 
 
Bachelor of Pharmaceutical Sciences-Ain Shams University 
 
 
Under the supervision of: Prof. Hassan M. E. Azzazy and Prof. Ricardo Franco  
 
Fall 2010 
ii 
 
The American University in Cairo 
Development of Prototype Gold Nanoparticle-Based Immunoassays for the 
detection of Plasmodium falciparum Hsp70 
A Thesis Submitted by Bassem Samy Guirgis 
To the Biotechnology Graduate Program, Fall 2010 
in partial fulfilment of the requirements for the degree of Master of Science in 
Biotechnology has been approved by: 
 
Prof. Hassan M.E. Azzazy 
Thesis Committee Chair / Advisor  
Affiliation: Associate Dean for Graduate Studies & Research; School of Sciences & 
Engineering; The American University In Cairo.  
 
Prof. Ricardo Franco 
Co-advisor 
Affiliation: Assistant Professor of Chemistry at the Faculdade de Ciências e 
Tecnologia, Universidade Nova de Lisboa, Portugal 
 
Prof. Miguel Prudêncio 
Thesis Committee Reader / External examiner 
Affiliation: Staff Scientist of the Malaria division of Instituto de Medicina Molecular, 
Portugal  
 
Prof. Suher Zada 
Thesis Committee Reader / Internal examiner 
Affiliation: Professor, Biology department; The American University In Cairo.  
 
Prof. Salah El Sheikh  
Observer 
Affiliation: Professor and associate chair, Department of Physics; The American 
University In Cairo.  
 
Program Director                         Date      
Dean                                      Date 
iii 
 
ACKNOWLEDGMENTS 
I would like to acknowledge my advisor Professor Hassan Azzazy (Associate Dean 
for Graduate Studies & Research; School of Sciences & Engineering; The American 
University In Cairo) for upgrading my writing as well as experimental skills and who 
was always with me throughout the previous 3 years. I would also like to 
acknowledge my co-advisor Professor Ricardo Franco (Assistant Professor of 
Chemistry at the Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, 
Portugal) who has helped me do my experimental part of my thesis in Portugal. I 
would also acknowledge Inês Gomes (Post Doc) who worked with me throughout the 
whole experimental project. Miguel Prudêncio (Staff Scientist of the Malaria division 
of Instituto de Medicina Molecular) and Claudia Sa e Cunha (Post Doc; Unidade de 
Malaria; Portugal) took me through the biological part of my thesis. I would 
acknowledge my Egyptian (Sherif Shawky and Mai Mansour) as well as my protégées 
colleagues (Joao Cortez and Inês Osorio) who were always hand in hand with me 
through my studies. The study was supported by FLAD (Luso-American Foundation) 
and FCT/MCTES: REQUIMTE; PTDC/BIO/66514/2006, PTDC/SAU-
BEB/66511/2006 and PTDC/QUI/64484/2006. STRC has provided me the graduate 
scholarship that helped a lot to reach what I have reached so far. Last but not least, I 
would acknowledge my mother that supported me financially and emotionally 
throughout the years. 
 
 
iv 
 
ABSTRACT 
The American University in Cairo  
Development of Prototype Gold Nanoparticle-Based Immunoassays for the 
detection of Plasmodium falciparum Hsp70 
 By: Bassem Samy Guirgis 
Under the supervision of: Prof. Hassan M. E. Azzazy and Prof. Ricardo Franco  
 
Biomedical nanotechnology is providing revolutionary opportunities for the rapid and 
simple diagnosis of many infectious diseases. About half RIWKHZRUOG¶VSRSXODWLRQ
are at risk of infection with malaria and diagnostic assays available either lack 
sensitivity and specificity or require expensive equipment, expertise or costly 
infrastructure; that are not usually available in countries where the disease is endemic. 
Thus, there is an urgent need to develop rapid, sensitive, and inexpensive diagnostic 
tests for malaria for both high- and low-resource settings. In this study, we developed 
two prototype gold nanoparticle (AuNP)-based immunoassays for the detection of 
Plasmodium falciparum Heat Shock Protein 70 (PfHsp70) antigen. PfHsp70 is a heat 
shock protein that has recently attracted attention as a novel therapeutic target. 
Monoclonal antibody (2E6) against PfHsp70 was produced and purified using 
immunoaffinity chromatography. Proof-of-concept for using Hsp70 as a diagnostic 
target was carried out by comparing the pellet of saponin-treated red blood cells of 
infected mice with that of non-infected mice or healthy humans, by Western blot. His-
tagged-PfHsp70 antigen was expressed from a genetically modified E. coli system 
and purified by affinity chromatography. For the development of the immunoassays, 
conjugation of mercaptoundecanoic acid (MUA) capped AuNPs with 2E6 was 
performed in presence and absence of protein cross-linkers. Characterization of the 
obtained bio-nanoconjugate (BNC) was performed using UV-visible 
spectrRSKRWRPHWU\DJDURVHJHOHOHFWURSKRUHVLVDQGȗ-potential measurements. 
Stability of the BNC against high salt concentrations and pH changes was also 
assessed. Based on the described antibody/antigen system, two prototype immuno-
competitive assays were developed in two distinct formats, namely, (i) a colorimetric 
chip assay, and (ii) a fluorescent quenching competitive assay. Proof-of-concept of 
chip assay allowed the comparison between conjugates prepared with and without 
NHS/EDC and it was found that non-NHS/EDC conjugates were more active. A 
fluorescence quenching competitive prototype assay was also developed which had a 
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limit of detection of 87 ng/mL (1.16 pM). As Hsp70 is a rather ubiquitous protein, 
other Plasmodium specific proteins that are secreted into the plasma of malaria 
patients will be identified in the future in the search of new diagnostic targets. Also 
further developments of the fluorescence quenching competitive assay will involve 
the use of cubical and decahedral AuNPs in order to try to increase the sensitivity of 
the assay as compared to spherical AuNPs.   
 
 
 
    
 
vi 
 
TABLE OF CONTENTS 
LIST OF FIGURES.         ix 
LIST OF TABLES.          xii 
APPENDIX.          xiii 
LIST OF ABBREVIATIONS.       xiv 
CHAPTER 1. INTRODUCTION.       1 
CHAPTER 2. LITERATURE REVIEW.      7 
2.1   Existing Malaria diagnostic assays.     7 
2.2   AuNP-based immunoassays.      9 
CHAPTER 3. MATERIALS AND METHODS     13 
3.1   Production, purification and activity of anti-PfHsp70 monoclonal 
antibody (2E6).        13 
3.1.1 Production of 2E6.      13 
3.1.2 Purification of 2E6 using affinity chromatography.  13 
3.1.3 Activity of 2E6 antibody.      15 
 
3.2   Hsp70 as a diagnostic target.      15 
3.2.1 Western blot analysis of plasma and whole blood of mice 
 infected with P. berghei.      15 
3.2.2 Western blot analysis of saponin pellets of RBCs of  
non-infected mice, of mice infected with P. berghei, and of 
 non-infected  human.      17 
3.2.3 Western blot analysis of saponin pellet of RBCs of  
non-infected mice and of mice infected with P. berghei,  
using actin as loading control.     18 
3.2.4 Western blot analysis of saponin pellet of RBCs of mice blood 
infected with P. berghei and of a human blood culture infected 
with P. falciparum.      18  
 
3.3   Conjugation of 2E6 antibodies to AuNPs.    19 
3.3.1 Synthesis of AuNPs.      19 
3.3.2 Functionalization of AuNPs with mercaptoundecanoic acid 
 and CALNN peptide.      19 
3.3.3 Conjugation of 2E6 antibodies to AuNP-MUA.   19 
3.3.4 Conjugation of 2E6 to AuNP-CALNN.    20 
 
3.4   Characterization of BNCs.      20 
3.4.1 UV-visible spectroscopy.      20 
vii 
 
3.4.2 Agarose gel electrophoresis.     21 
3.4.3 Zeta (ȗ)-potential.       23 
3.5   Stability of AuNP-MUA-2E6 conjugates.    24 
3.5.1 NaCl method.       24 
3.5.2 pH aggregation.       24 
3.6   PfHsp70 expression.       24 
3.6.1 Transformation of pQE30/Pf+VSLQWR5RVHWWD%OXHFHOOV. 24 
3.6.2 Expression of PfHsp70 under different induction conditions. 25 
3.6.3 Expression of PfHsp70 under optimum conditions in a large  
scale.        26 
3.7   Purification of PfHsp70 using Ni-NTA column.   26 
3.8   Labelling of PfHsp70 with Cy3B.     27 
3.9   Chip assay.        28 
3.10 Fluorescence quenching competitive assay.    29 
CHAPTER 4. RESULTS.        31 
4.1  Production, purification and activity of anti-PfHsp70 antibody (2E6). 31  
4.2   Hsp70 as a diagnostic target.      31 
4.2.1 Western blot analysis of plasma and whole blood of mice  
infected with P. berghei.      31 
4.2.2 Western blot analysis of saponin pellets of RBCs of 
non-infected mice, of mice infected with P. berghei, and of 
non-infected  human.      32 
4.2.3 Western blot analysis of saponin pellet of RBCs of mice blood 
infected with P. berghei and of human blood culture infected   
with P. falciparum.       32 
 
4.3   AuNP synthesis and functionalization with MUA.   33 
4.4   Characterization of BNCs.      33 
4.4.1 UV-visible spectroscopy.      33 
4.4.2 Agarose gel electrophoresis.      33 
=HWDȗ-potential.       34 
4.5   Stability of AuNP-MUA-2E6 BNCs.     35 
4.5.1 NaCl method.       35 
4.5.2 pH aggregation.       35 
4.6   PfHsp70 expression.       36 
4.6.1 Transformation of pQE30/Pf+VSLQWR5RVHWWD%OXHFHlls. 36 
4.6.2 Expression of PfHsp70 under different induction conditions. 36 
4.7   Purification of PfHsp70 using Ni-NTA column.   37 
4.8   Labelling of PfHsp70 with Cy3B.     37 
viii 
 
4.9   Chip Assay.        38 
4.10  Fluorescence quenching competitive assay.    38 
CHAPTER 5. DISCUSSION.       40 
5.1   Purification and specificity of 2E6 antibody.    40 
5.2   Synthesis and functionalization of AuNPs and characterization of 
 AuNP-MUA-2E6 BNCs.      42 
5.3   PfHsp70 expression.       44 
5.4   Purification and Cy3B-labelling of PfHsp70.    45 
5.5   Chip Assay.        46 
5.6   Fluorescence quenching competitive assay.    46 
CHAPTER 6. CONCLUSIONS.       47 
6.1 Summary.         47 
6.2 Future plans.        47 
CHAPTER 7. REFERENCES.   49 
CHAPTER 8. LIST OF FIGURES.       54 
CHAPTER 9. LIST OF TABLES.       98 
CHAPTER 10. APPENDIX.        102 
 
ix 
 
LIST OF FIGURES 
Figure 1. Malaria life cycle.         54 
 
Figure 2. Structure of Hsp70-1.        55 
 
Figure 3. Surface Plasmon Resonance of AuNPs.      56 
 
Figure 4. Giemsa stained RBCs of Plasmodium falciparum infected patient 
showing several P. falciparum ring structures.     57 
 
Figure 5. Principle of the fluorescence quenching competitive assay for detection 
of PfHsp70.          58 
 
Figure 6. BCA protein assay principle.       59 
 
Figure 7. SDS-PAGE (12.5%) analysis of 2E6 antibody purified using two step 
Protein G affinity chromatography columns.      60  
 
Figure 8. Molecular weight values of the two bands of 2E6 (corresponding to 
heavy and light chains) shown on SDS-PAGE, as calculated based on calibration 
curve.            61 
 
Figure 9. Standard curve of BCA test for determining concentration of purified 
2E6 antibody.          62  
 
Figure 10. Western blot analysis of plasma of non-infected mice (A) and of mice 
blood infected with Plasmodium berghei (B) using 2E6 antibody.    63 
 
Figure 11. Western blot analysis of whole blood of non-infected mice (A) and of 
 mice infected with Plasmodium berghei (B) using 2E6 antibody.   64 
 
Figure 12. A: Western blot analysis comparing plasma, saponin supernatant 
(RBC lysate) and saponin pellet of non-infected mice; mice infected with  
Plasmodium berghei; and non-infected human blood, using 2E6 antibody.  
B: Western blot analysis comparing saponin pellet of non-infected mice; mice 
infected with Plasmodium berghei; and non-infected human blood, using 2E6 
antibody. C: Western blot analysis showing undiluted saponin supernatant and 
saponin pellet of non-infected human blood, using 2E6 antibody.   65  
 
Figure 13. Western blot analysis of non-infected mice saponin pellet and of mice 
infected with Plasmodium berghei, using actin as loading control.   66 
 
Figure 14. Western blot analysis of saponin pellets of RBCs of mice infected 
with Plasmodium berghei and of human blood culture infected with 
Plasmodium falciparum.        67 
 
Figure 15. Absorbance spectrum of AuNP-MUA before and after 2E6 
conjugation showing a shift in peak maximum from 521 nm to 530 nm for 
both NHS/EDC and non-NHS/EDC BNCs.      68 
 
x 
 
Figure 16. Unstained agarose gel electrophoresis of AuNPs and  
bionanoconjugates (BNCs) prepared with different molar ratios of BSA to AuNP-
MUA.            69 
 
Figure 17. Unstained agarose gel electrophoresis of AuNP-MUA-2E6 conjugates 
prepared with different NHS/EDC concentrations showing that 0.6-1.2 mM and 
1.4-2.8 mM concentration of NHS and EDC, respectively, was found to be 
optimal for cross-linking.        71 
 
Figure 18. Unstained agarose gel electrophoresis of AuNP-MUA-2E6 conjugates 
(with and without NHS/EDC) prepared with different molar ratios of 2E6 to  
AuNP-MUA.           72 
 
Figure 19. Unstained agarose gel electrophoresis of AuNP-CALNN-2E6  
conjugates prepared with different NHS/EDC concentrations.   73 
 
)LJXUHȗ-potential of non-NHS/EDC and NHS/EDC AuNP-MUA-2E6 
bionanoconjugates.          74 
 
Figure 21. Absorbance spectra of non-NHS/EDC (A) and NHS/EDC (B) AuNP-
MUA-2E6 BNCs after adding an equal volume of 5M NaCl.    75 
 
Figure 22. Ratio of absorbance of aggregated forms (659 nm) to non-aggregated 
forms (530nm) after adding an equal volume of 5 M NaCl vs. the molar ratio of 
2E6 to AuNP-MUA of BNCs prepared with and without NHS/EDC.   76 
 
Figure 23. A: Visible absorbance spectra of 1nM AuNP-MUA at different pH 
values. B: Ratio of absorbance of aggregated forms of 1nM AuNP-MUA  
(666 nm) to that of non-aggregated forms (523 nm) at different pH values.  77 
 
Figure 24. Absorbance spectra of AuNP-MUA-2E6 BNCs prepared in the  
presence of NHS/EDC at different pH values.     78  
 
Figure 25. pH aggregation study of AuNP-MUA-2E6 BNCs prepared in the 
presence of NHS/EDC showing ratio of absorbance of aggregated forms of BNCs 
to that of non-aggregated forms at different pH values.    79 
 
Figure 26. Absorbance spectra of AuNP-MUA-2E6 BNCs prepared in the  
absence of NHS/EDC at different pH values.     80 
 
Figure 27. pH aggregation study of AuNP-MUA-2E6 BNCs prepared in the 
absence of NHS/EDC showing ratio of absorbance of aggregated forms of BNCs  
to that of non-aggregated forms at different pH values.    81 
 
Figure 28. LB agar plates having ampicillin and chloramphenicol showing 
5RVHWWD%OXHWUDQVIRUPHGFHOOV.        82  
 
Figure 29. Bacterial growth curve showing optical density (O.D600nm) vs time 
under different induction conditions.       83 
 
xi 
 
Figure 30 A. SDS-PAGE (10%) analysis of pellets after resuspension in lysis 
buffer of cultures under different induction conditions. B. Western blot analysis 
of pellets after resuspension in lysis buffer of cultures under different induction 
conditions.           84 
 
Figure 31. SDS-PAGE (10%) and Western blot analysis of pellets after  
resuspension in lysis buffer of transformed and non-transformed 5RVHWWD%OXH 
cells.            86  
 
Figure 32. SDS-PAGE (10%) analysis of bacterial culture containing PfHsp70 
before and after Ni-NTA purification.      87   
 
Figure 33. Absorbance spectra of free Cy3B (red trace) and of Cy3B-labelled 
PfHsp70 (blue trace).          88 
 
Figure 34. Chip competitive assay principle.      89 
Figure 35. Prototype chip assay utilizing non-NHS/EDC bionanoconjugates.  90 
Figure 36. Prototype chip assay utilizing NHS/EDC bionanoconjugates.  91 
 
Figure 37. Quenching effect of AuNP-MUA on fluorescence emission of Cy3B-
labelled PfHsp70         92 
 
Figure 38. Fluorescence quenching competitive assay     93 
 
Figure 39. Structure of IgG antibody       95 
 
Figure 40. Principle of NHS/EDC cross-linking     96   
 
Figure 41. Fluorescence emission band of the Cy3B-labelled antigen overlaps 
with the absorbance spectra of antibody-conjugated AuNPs (different AuNP 
shapes: spherical, cubical and decahedral)      97 
xii 
 
LIST OF TABLES 
Table 1. The advantages and disadvantages of the different diagnostic assays 
for malaria.           98 
 
Table 2. Composition of SDS-PAGE.       99 
 
Table 3. Volume/concentration  of AuNP-MUA added to quench fluorescence 
emitted by Cy3B-labelled PfHsp70.                  100 
 
Table 4. Determination of the concentration of 2E6 antibody using BCA.            101 
xiii 
 
 
APPENDIX 
 
Table 1. Comparison between antibody binding to protein A and G««««« 
 
Table 2. Comparison between FITC and Cy3B«««««««««««««« 
 
 
xiv 
 
LIST OF ABBREVIATIONS 
ACTs: Artemisinin-based combination therapies 
AMA: Apical membrane antigen   
ASV: Anodic stripping voltammetry  
AuNP: Gold nanoparticle 
BCA: Bicinchoninic acid. 
BNC: Bio-nanoconjugate 
BSA: Bovine serum albumin 
CSP: Circumsporozoite protein 
cTnT: Cardiac troponin T 
EBA: Erythrocyte-binding antigen 
EDC: 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride 
EXP: Exported protein  
FITC: Fluorescein isothiocyanate 
FT: Flow through 
GFR: Glomerular filtration rate 
GLURP: Glutamate-rich protein  
HBsAg: Hepatitis B surface antigen 
HRP: Horseradish peroxidase 
HRP-2: Histidine rich protein-2 
ICP: Inductive Coupled Plasma 
IPTG: ,VRSURS\Oȕ-D-1-thiogalactopyranoside 
LB: Luria Broth  
LOD: Limit of detection 
LSA: Liver stage antigens  
MSP: Merozoite surface proteins  
MUA: Mercaptoundecanoic acid 
NHS: N-hydroxysuccinimide 
PbHsp70: Plasmodium berghei heat shock protein 70 
PBS: Phosphate buffer saline 
PCR: Polymerase chain reaction 
PfEMP1: Erythrocyte protein 1 antigen 
PfHsp70: Plasmodium falciparum heat shock protein 70 
pLDH: Plasmodium lactate dehydrogenase 
xv 
 
PMSF: Phenyl methyl sulphonyl fluoride  
RBCs: Red blood cells 
RDTs: Rapid diagnostic tests 
SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SPIA: Sol particle immunoassays 
SPR: Surface Plasmon Resonance 
SSP: Sporozoite surface protein  
TEM: Transmission Electron Microscopy 
 
 
 
 
1 
 
CHAPTER 1. INTRODUCTION 
Malaria is a protozoan infection transmitted via female Anopheles mosquito bites. It  
LVRQHRIWKHPRVWFRPPRQLQIHFWLRQVZRUOGZLGHDQGDERXWKDOIRIWKHZRUOG¶V
population live in malaria-endemic areas including regions in Asia, Central and South 
America, Africa, Oceania, and the Caribbean islands1. In 2008, 247 million malaria 
cases were diagnosed that resulted in the death of about one million patients, mainly 
African children. It is reported that in Africa, malaria results in the death of a child 
every 45 sec2. Malaria infection rates are increasing worldwide and imported malaria 
has  increased by 400% in industrialized countries in the last 20 years3.  
Patients may be infected with one or more of the 4 main species of 
Plasmodium (P.); namely P. falciparum, P. vivax, P. ovale and P. malariae1-2. P. 
falciparum and P. vivax are the most common2. P. falciparum is the most fatal species 
and is the predominant species in Africa, Papua New Guinea and parts of Asia. P. 
vivax is rarely fatal but can cause severe symptoms and is most common in Central 
America, the Indian subcontinent, and China. P malariae is less common and the 
majority of cases are reported in sub-Saharan Africa. P.  ovale is the rarest species, 
with the majority of cases reported in sub-Saharan West Africa1. 
The most common symptoms of malaria include fever (more than 92% of 
cases), chills (79%), headaches (70%), and diaphoresis (64%)4. Other symptoms 
include dizziness, malaise, myalgia, abdominal pain, nausea, vomiting, mild diarrhea  
and dry cough4. Common signs include fever, tachycardia, jaundice, pallor, 
orthostatic hypotension, hepatomegaly and splenomegaly. P. falciparum malaria may 
lead to severe complications including cerebral malaria, pulmonary edema, acute 
renal failure, severe anaemia, and/or bleeding, acidosis and hypoglycaemia. These 
complications can lead to death within hours or days from the start of symptoms4.  
The life cycle of P. falciparum can be divided into asexual reproduction in 
mammalians and sexual reproduction in female Anopheles mosquito (figure 1)5-6. In 
mammals (including humans), the life cycle starts with a bite of the individual by an 
infected mosquito. Sporozoites are released from the saliva of the mosquito into the 
patient¶s blood and then migrate to the liver. In liver cells (hepatocytes), asexual 
reproduction occurs leading to the production of merozoites that are released into the 
blood stream with the rupture of infected hepatocytes. Merozoites invade red blood 
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cells (RBCs) and start the erythrocytic cycle in which asexual replication occurs. 
Release of merozoites from infected ruptured RBCs allow invasion of more RBCs. 
This cycle keeps on repeating and after some time, some of the merozoites start to 
form male and female sexual forms in the patient blood. During the feeding of a 
female Anopheles mosquito, these sexual forms are taken up by the mosquito leading 
to the formation of the zygote in the midgut of the mosquito. The zygote formed 
matures to generate ookinetes that divide within oocysts (on external gut wall) to 
generate thousands of sporozoites. Sporozoites then migrate to the salivary gland 
ready to be injected with the next mosquito blood meal5-6.      
 To reduce the risk of infection transmission, vector control is mandatory. This 
can be accomplished by using insecticide-treated nets, indoor residual insecticidal 
sprays, as well as other approaches including the reduction of standing water habitats 
where mosquitoes breed. Many drugs can be used for the treatment of malaria 
allowing shortening of infection duration, prevention of complications and avoiding 
deaths2. According to the WHO, the best available medication for malaria treatment 
(especially P. falciparum) is the use of the so called artemisinin-based combination 
therapies (ACTs)2.  
Until the present day, no completely effective vaccine is available, although 
many trials have been reported2. Many attempts to develop a vaccine against malaria 
has been reported but failure to fully develop a vaccine for malaria is suggested to be 
due to complexity of the parasite (expresses more than 5000 proteins during its life 
cycle), complexity in the interaction between parasite biology and host immunity, and 
finally scarcity in dedicated resources and global cooperation7. Vaccines developed so 
far target either the pre-erythrocytic, the asexual erythrocytic or the sexual stages of 
the parasite or others8. Pre-erythrocytic vaccine is potentially useful for travellers. The 
theory is inducing the development of antibodies that either neutralize sporozoites 
(preventing them from infecting hepatocytes) or triggering a cell-mediated immune 
resulting in death of infected hepatocytes. These include circumsporozoite protein 
(CSP) vaccines that incorporates CSP protein that is expressed at the surface of the 
sporozoite and of the infected hepatocyte8. During clinical trials on volunteers, the 
only CSP vaccine that was effective was RTS,S  (C-terminal parts of the CS protein 
bound to S protein of HBV) when combined with a suitable adjuvant 
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(GlaxoSmithKline proprietary AS02A composed of MPL, QS21 and an oil-in-water 
emulsion) that resulted in 50%  protection during Phase IIa and 30-60% in field 
trials7. Currently, a Phase III trial is being undergone for the RTS,S vaccine8. The 
second class of CSP vaccines are plasmid DNA vaccines and live recombinant 
vaccines that encode CSP protein. Although in mouse models, Plasmid DNA vaccines 
DOORZHGIRUHIILFLHQWKXPRUDODQGFHOOXODULPPXQHUHVSRQVHVLWGLGQ¶WSURYLde 
efficient protection in humans. In addition, multiple-antigen DNA vaccine were also 
developed such as MuStDO-5 that encodes CSP, liver stage antigens 1 and 3 (LSA-1 
and -3), exported protein 1 (EXP1), and the sporozoite surface protein 2 (SSP2). 
Although in mice and rabbits MuStDO-5 was found to be safe and well tolerated, it 
only showed weak immunogenicity in primates with no evidence of protection (Phase 
IIa)8. 
Asexual blood-stage (erythrocytic stage) vaccines have been developed as 
potentially useful for countries where malaria is endemic. The theory is inducing the 
development of antibodies that either inactivate merozoites or will recognize malarial 
antigens present on the surface of infected RBCs leading to antibody-dependent 
cellular cytotoxicity, complement lysis and/or trigger T-cell responses, inhibiting the 
development of parasites within RBCs8. The most advanced erythrocytic stage 
vaccine is based on the use of merozoite surface proteins 1 (MSP-1), 2 (MSP-2) and 3 
(MSP-3), the apical membrane antigen 1 (AMA-1) and the glutamate-rich protein 
(GLURP). A successful vaccine was MSP-1 formulated in AS02 adjuvant that was 
found to be safe and immunogenetic in humans. Similarly, AMA-1 protein formulated 
in AS02 adjuvant caused protection against malaria in rodents and non human 
primates. Another successful vaccine was PfCP-2.9 that is a fusion antigen of MSP-
1/AMA-1 formulated with Montanide ISA adjuvant8. This vaccine showed good 
immunogenicity in both rabbits and non-human primates. MSP-3 based vaccine was 
found to be safe and to successfully induce long-lasting antibodies that display 
antibody-dependent cellular inhibition activity in mice (phase I). Sexual stage have 
been developed that are potentially useful to reduce transmission of the parasite to 
hosts. Candidates include P. falciparum and P. Vivax ookinete surface antigens 
(Pfs25; Pfs28 and Pvs25; Pvs28). Phase I study for Pvs25 showed modest 
immunogenicity8.  
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Other antigens are still being tested as efficient vaccines including MSP-4, -5, 
-8 and -9, erythrocyte-binding antigen (EBA-175), pregnancy-associated malaria, the 
erythrocyte protein 1 (PfEMP1) antigen and PfHsp708-9. Finally a different approach 
is to use attenuated parasite (such as attenuated sporozoites) to induce immunity. 
Whole irradiated sporozoites (Sanaria) is in its phase I10. Challenges in producing 
attenuated vaccines include producing sporozoites in large amounts, quality control 
during production, process monitoring, stability and the price of the product8.  
 Regarding malaria diagnosis, available methods either lack sensitivity and 
specificity or require expensive equipment, expertise or costly infrastructure; that are 
not usually available in countries where the disease is endemic. Thus it is clear that 
there is a need for a sensitive and cost effective method to test for malaria. It is 
important to note that it is estimated that with the aid of proper diagnosis, more than 
100,000 deaths may be sparred and about 400 million unnecessary treatments may be 
averted 3. Also finding novel diagnostic targets for P. falciparum may help in 
developing more sensitive tests.  
The present study investigated the possibility of using PfHsp70 as a diagnostic 
target for malaria and the development of two prototype AuNP-based assays for its 
detection. PfHsp70 is a member of the heat shock protein family that is produced by 
the parasite to protect from stress during its stay within the different hosts. Hsp70 
mainly act as molecular chaperones, binding to proteins in their non-native forms and 
helping their refolding to native forms 11. Also it was found that Hsp70 helps in the 
assembly or disassembly of multiprotein complexes, protein translocation, protein 
degradation, signal transduction and prion replication12. PfHsp70 is expressed in all 
asexual blood stages of the parasite11.  
As expected from its name, PfHsp70 is heat-inducible, meaning that it is 
expressed at higher levels when the parasite is exposed to elevated temperatures 
protecting the parasite against patients fever 13. The underlying mechanism is that at 
high temperatures, the transcriptional factor ³KHDW-VKRFNIDFWRU´(HSF) binds more 
efficiently to heat-shock elements (HSE; conserved regions upstream the gene coding 
for Hsp70) leading to higher gene expression13.   
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The structure of PfHsp70 is similar to that of eukaryotic Hsp70, presenting 
three domains namely; N-terminal ATPase domain (45 kDa), a central substrate 
binding domain (15 kDa) and a C-terminal domain (10 kDa) (figure 2) 13-14. Malaria 
Hsps are antigenic to human probably due to non-homologous sequences at the C-
terminus of the proteins13.   
Gold nanoparticles (AuNP) display unique physical properties due to their 
nano-size. AuNPs have intense absorbance and scattering properties due to Surface 
Plasmon Resonance (SPR). When an oscillating electric field interacts with the free 
conductive band of electrons at the surface of the AuNP, collective dipolar oscillation 
of the electrons occurs. This is called Surface Plasmon15 (figure 3). SPR occurs when 
the frequency of the exciting light is similar to that of the Surface Plasmon. The 
absorption cross-section of AuNPs was found to be 104 to 105 folds higher than that of 
the strongest absorbing Rhodamine-6G dye molecule. Regarding the scattering of 
AuNP, 80 nm AuNP was found to have 105 folds higher scattering than fluorescein15. 
When AuNPs come close together, Plasmon-Plasmon coupling occurs leading to 
energy loss and a shift in the absorbance peak maximum to a longer wavelength and 
thus a change in color from red to blue15.   
 Another advantage of AuNPs is that their optical properties can be tuned by 
varying both their size and shape. For example, small particles (such as 20 nm) show 
SPR absorption with negligible scattering properties15. However, larger particles 
(such as 80 nm) have high scattering properties and thus they are chosen in scattering 
based assays15. AuNPs can also be easily synthesized in different size ranges (9-120 
nm) and conjugated to biomolecules (protein and oligonucleotides)16. These unique 
properties allow AuNP-based assays to be highly sensitive, and many can be used in 
point of care testing kits providing fast, simple and relatively inexpensive detection. 
Immunological AuNP-based assays can be classified according to signal 
detection techniques into visual (dipsticks and sol particle immunoassays), 
spectrophotometric, fluorescence quenching , immuno-PCR, scattering, scanometric, 
chemiluminescence, real-time refractometric, surface-enhanced raman scattering and 
electronic detection based assays 17.  
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In the present study two prototype AuNP-based assays for the detection of the 
malarial antigen, PfHsp70 were developed. The first is a competitive-based chip assay 
that allows for the rapid and simple qualitative detection of malarial antigens and can 
be used as a field assay. The second is a fluorescence quenching competitive assay 
that is sensitive, rapid and simple to perform. The assay can be used in advanced 
laboratories and has the potential for quantitative detection of malarial antigens.   
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CHAPTER 2. LITERATURE REVIEW 
2.1   Existing Malaria diagnostic assays 
Diagnostic tests available for malaria either lack sensitivity and specificity or require 
expensive equipment, expertise or costly infrastructure; that are not usually available 
in countries where the disease is endemic. Malaria diagnostic tests include direct 
methods that detect the parasite or parasitic components such as light microscopical 
analysis, immunochromatographic assays and nucleic acid detection tests and indirect 
tests such as flow cytometry and laser desorption mass spectroscopy. Light 
microscopical analysis is still considered the standard method for malarial diagnosis. 
It simply involves direct visualization of malaria parasites in Giemsa-stained blood 
samples allowing the detection as well as the differentiation between Plasmodium spp 
(figure 4)18. Light microscopical analysis may also allow the determination of 
parasitemia level. This method has a low direct cost ranging from 0.4-0.7 US$ per 
slide. However, it is labour intensive and requires technical expertise, with a low turn-
around time (the process is slow)3,19-20. The sensitivity of the light microscopy method 
is reported to range from 50-100 parasites per µL in routine labs; however in expert 
labs the sensitivity may reach 10 parasites per µL 3. Thus, much simpler and easier to 
interpret methods with higher turn-around time have been developed including 
immunochromatographic assays or what is also named rapid diagnostic tests (RDTs). 
These include dipsticks and cassettes that allow the detection of different malarial 
antigens including parasite histidine rich protein (HRP-2), lactate dehydrogenase 
(pLDH), and aldolase3. The sensitivity of this method may be comparable to that of 
microscopy (100 parasites per µL) but it is much simpler and easier, requiring 
minimal infrastructure and expertise3. However, the sensitivity of such tests may be 
dramatically affected by in field conditions such as heat and humidity21. These tests 
may also give false positives due to cross reactivity with rheumatoid factor that is 
present in high titre in blood of patients suffering from certain diseases such as 
rheumatoid arthritis22.  
HRP-2 is an antigen present only in P. falciparum and rapid tests testing HRP-
2 were found to be most sensitive for the detection of P falciparum3. However, the 
two main drawbacks of HRP-2-based RDTs are that, on one hand, the positivity may 
remain even 3 weeks after disease resolution and on the other hand, this antigen is 
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only expressed in P. falciparum and thus this RDT cannot be used for the detection of 
other Plasmodium spp3. The latter drawback has been overcome by using RDTs 
utilizing both HRP-2 and aldolase. Aldolase is a pan antigen (present in the different 
Plasmodium spp) and thus assays utilizing both aldolase and HRP-2 can detect both 
falciparum and non-falciparum species. However, the sensitivity and specificity for 
detecting non-falciparum infection is low for aldolase based assays (46 - 93% for P. 
vivax and 7 - 80% for P. ovale or P. malariae)3,23. 
pLDH is a species-specific antigen utilized in RDTs  and thus can be used for 
the differentiation between the diff P. spp. However, tests based on pLDH have a 
lower sensitivity in detecting P. falciparum infection (sensitivity of pLDH tests is 
67% vs 93% for HRP-2 based tests) compared to HRP-2-based tests3, 24. The 
sensitivity of pLDH for non-falciparum species is however superior to aldolase-based 
tests (P. vivax 62 - 95% and for P. ovale and P. malariae 36 - 95%) 3,23. pLDH level 
changes proportional to the parasitemia level and thus pLDH based assays can be 
utilized for therapeutic monitoring3.    
A more sensitive method for the detection of malarial infection is the detection 
of parasitic nucleic acid via PCR. This method is very sensitive allowing the detection 
of 1-5 parasites per µL and can be used to differentiate between malarial species. 
Although this method allows for high throughput analysis, method standardization as 
well as rapid detection, the capital and operating costs are high. Advanced 
infrastructure and trained personnel are also crucial to prevent contamination3,25-26.  
The second group of tests that can also be used to detect malarial infection are 
the indirect tests such as flow cytometry and laser desorption mass spectrometry. 
Flow cytometry can be used to detect hemozoin within phagocytes3,27-29. Hemozoin is 
produced within RBC infected cells where malaria digests hemoglobin and promotes 
its crystallization, forming hemozoin that is stored in acidic vacuoles. The detection of 
hemozoin is thus an indirect marker of malaria infection which can be accomplished 
by measuring the depolarization of laser in a flow cytometer channel3. This method 
uses standard hematology analyzers and is thus potentially useful for diagnosing 
clinically un-suspected imported malaria. However, this technology is expensive and 
diagnosis should be confirmed via other methods3. Another technique to measure 
hemozoin is laser desorption mass spectroscopy. When hemozoin crystals absorb 
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ultraviolet photons, intact heme is released giving spectra of the parent molecule as 
well as its molecular ion fragments. In non-infected blood samples, heme bound to 
haemoglobin is not rapidly ionized and thus is not detected3. The sensitivity of this 
method is 10 parasites per µL30. The method is rapid, easy to use and requires low 
sample volume. However, the cost of the equipment is very high and until now this 
method cannot differentiate between the different P. sp 3. Table 1 summarizes the 
advantages and disadvantages of the different diagnostic assays available for malaria.   
It is thus clear that there is still a need for the development of a diagnostic 
assay for the detection of malaria antigens that is sensitive, rapid, simple and cost 
effective.  
2.2   AuNP-based immunoassays 
Immunological AuNP-based assays can be classified according to signal detection 
techniques into visual (dipsticks and solution phase), fluorescence quenching, 
scattering and electronic detection based assays and others as mentioned earlier 
(under introduction)17. Tanaka et al.31 developed a sol particle visual immunoassay 
for the determination of cystatin C (endogenous marker of glomerular filtration rate 
(GFR)). In the presence of cystatin C, aggregation of antibody conjugated-AuNPs 
occur leading to change in color and shift in absorption peak maxima. Detection limit 
was reported to be 0.2 mg/L and linearity was achieved in the range between 0.2 to 8 
mg/L31. Liu et al. 32developed a scattering-based homogenous immunoassay for the 
detection of mouse IgG. In the presence of mouse IgG antibody, aggregation occurs to 
anti-mouse conjugated AuNPs. Aggregation can then be detected and quantified using 
dynamic light scattering. The detection limit reported was 0.5 ng/ml32. Shen et al. 
33developed an immunoassay based on the electrochemical properties of AuNPs. The 
assay utilizes anodic stripping voltammetry (ASV) for the detection of hepatitis B 
surface antigen (HBsAg). Magnetic nanoparticle-labelled anti-HBsAg and AuNP-
labelled with a matched pair of anti-HBsAg were added to a sample having HBsAg. 
After incubation, the sandwiched complex was magnetically separated, washed and 
enhanced by adding copper enhancer solution (copper sulphate plus ascorbic acid). 
The sandwiched complex (with copper deposited on the surface of AuNPs) was 
separated and copper solubilised using nitric acid. The concentration of copper ions 
released was then measured using ASV. Concentration of copper ions measured 
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corresponded to the concentration of the HBsAg present in the sample. The detection 
limit of the assay was reported to be 87 pg/ml and the dynamic range lied between 0.1 
to 1500 ng/ml33.  
Since this study involved the development of AuNP-based competitive chip as 
well as fluorescence quenching immunoassay, literature review will focus more on 
assays based on these platforms. Competitive as well as sandwich based colorimetric 
chip assays have been developed for the detection of several toxins and antigens 
including P. spp antigens3. Commercially available dipsticks are available that detect 
one or a combination of the three antigens (HRP-2, pLDH and aldolase) mentioned 
previously under introduction34. 
Regarding fluorescence quenching AuNP-based immunoassays, studies have 
reported the development of competitive and sandwich based assays for the detection 
of different antigens, markers or drugs35-39. The developed sandwich immunoassays 
were either in solution phase or immobilized on a support. Ao and collaborators35 
developed a solution based sandwich fluoroimmunoassay for the detection of alpha 
fetoprotein, in which magnetic nanoparticles were labelled with a polyclonal antibody 
and the AuNPs were labelled with monoclonal antibodies. Alpha-fetoprotein was 
sandwiched between the two antibody-functionalized nanoparticles. The 
immunocomplex was easily separated from the surrounding solution using a magnetic 
field 35. The remaining supernatant which contains free gold probes (in case of 
positive sample there will be less than in case of the negative sample) was allowed to 
quench the fluorescence of fluorescein isothiocyanate (FITC). Fluorescence of FITC 
at 516 nm was then measured which was proportional to the amount of alpha-
fetoprotein present in sample. The reported detection limit was 0.17 nM and the 
measurement range was from 15 to 400 ng/mL35. Recently, Mayilo et al. developed 
another sandwich fluoroimmunoassay in solution form for the detection of cardiac 
troponin T (cTnT)36. Two monoclonal antibodies were used in this study, the first and 
second antibodies were labelled with AuNPs and fluorescent dyes, respectively. In the 
presence of antigen, the distance between the fluorescent dye and the AuNP decreased 
leading to fluorescence quenching. The limit of detection in this study was 0.02 nM 
(0.7 ng/mL)36. An example of an immobilized sandwich fluoroimmunoassay is that 
developed by Peng et al. 37 for the detection of IgG. IgG was captured by a primary 
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antibody immobilized to polystyrene microwells, followed by the addition of a 
secondary AuNP-labelled antibody. The formed immunocomplex was then 
dissociated and the supernatant was added to a solution of fluorescein. If the sample 
was positive, then the level of AuNP-labelled secondary antibody immobilized to the 
microtiter plates will be high and so will be the amount of AuNPs in the supernatant 
after dissociation. Thus the fluorescence quenching of fluorescein will be high as 
determined by measurements at 517 nm. An inverse proportional relationship was 
achieved between the logarithmic value of IgG concentration and fluorescence 
intensity at 517 nm. The detection limit reported was 4.7 ng/mL and the dynamic 
range was 10 - 5,000 ng/mL 37.  
Other studies have reported competitive surface and solution based 
immunofluorometric assays. Matveeva et al. 38 has developed a surface based 
competitive fluoroimmunoassay. In this study, AuNPs were covalently linked to 
indium tin oxide coated glass slide and antibodies against the analyte were non-
covalently bound to the AuNPs. Then an analyte-fluorophore conjugate was added 
and the fluorescence emission value was low due to quenching by AuNPs. The 
sample containing unlabelled analyte was then added that competed with the 
immobilized analyte-fluorophore conjugate and fluorescence emission was restored. 
To further increase the fluorescence enhancement, the supernatant containing the 
displaced analyte-fluorophore conjugate was allowed to react with another surface 
having immobilized silver shelled AuNPs that are bound to anti-fluorophore 
antibodies. When the analyte-fluorophore conjugate were bound to this surface via 
anti-fluorophore antibodies, the signal was enhanced by the effect of the silver shelled 
AuNP (fluorescence emission was 7 - 8 times that of gold surface). Mayilo S et al 39  
developed a homogenous solution based competitive immunoassay for the detection 
of the hapten digoxigenin. In this study, digoxigenin in the analyte competes with 
Cy3B (fluorophore)-labelled digoxigenin for antibody-conjugated-AuNP 
(bionanoconjugates; BNCs) binding sites. In case of positive samples, BNC binds to 
digoxigenin in the sample and thus Cy3B-labelled digoxigenin is inhibited from 
binding and low quenching occurs. In blank samples, Cy3B-labelled digoxigenin 
binds easily to the BNC and strong quenching occurs. Linearity was reported in the 
range from 0.5-3 ng/mL. The limit of detection (LOD) and limit of quantitation were 
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0.2 and 0.6 ng/mL, respectively. In this study, Mayilo S et al¶V39 method was 
modified to detect PfHsp70 antigen and the principle of the assay is shown in figure 5. 
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 CHAPTER 3. MATERIALS AND METHODS 
3.1   Production, purification and activity of anti-PfHsp70 monoclonal antibody 
(2E6)  
3.1.1 Production of 2E6 
All materials used in this study were purchased from Sigma Aldrich, Germany unless 
otherwise stated. A hybridoma culture was grown using standard scale up culturing 
conditions to produce 2.6 L of culture containing 2E6 monoclonal antibody (antibody 
against PfHsp70; IgG). Protein precipitation was performed using 50% w/v 
ammonium sulphate solution, by gradually adding an equal volume of ammonium 
sulphate saturated solution at 4oC. This allowed the gradual precipitation of proteins. 
The precipitate was collected by centrifugation (10,000 rpm for 10 min at 4oC) and 
then resuspended in  phosphate buffer saline (PBS; about 40 mL) and excess salts 
were removed by 2x overnight dialysis (pore size 30 kDa) against 5L PBS. After 
dialysis, 100 mL of impure 2E6-containing solution was obtained. The solution was 
centrifuged at 10,000 rpm for 30 min at 4oC to remove precipitates and the 
supernatant was concentrated to 35 mL by ultrafiltration using D³diaflo´$PLFRQ
system with gentle mixing at 4oC (cut-off value of membrane was 30 kDa; 
Ultrafiltration membrane Millipore, Germany)40.  
 
3.1.2 Purification of 2E6 using affinity chromatography 
Purification of 2E6 antibody was done in two steps: the first step using Protein G 
Sepharose 4 Fast Flow (GE; 17-0618-01, Germany) and the second step using PD 
SpinTrap G-25 columns (GE; 28-9031-34, Germany) according to manufacturer¶s 
protocols41. Protein G Sepharose 4 Fast Flow (1.6 mL) was added to a column support 
and was equilibrated with 5-10 column volumes of binding buffer (20 mM sodium 
phosphate; pH = 7). Then 1.6 mL of concentrated impure antibody solution (60 
mg/mL of total protein determined using BCA test [see below]) was added to the 
column. The column was then washed with binding solution until UV absorbance at 
280 nm reached baseline. Then 10 mL of elution buffer (glycine HCl 0.1 M pH = 2.7; 
Riedel-de-Haen, Germany) was added to the column to elute the antibody. The first 5 
drops were discarded and the rest was collected into tubes containing 400 µL of Tris-
HCl buffer (1 M pH = 9; neutralizing buffer) to neutralize the pH of the solution to 
prevent 2E6 antibody from being denatured by the low pH of the elution buffer. The 
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column was then regenerated by washing with 5 - 10 column volumes of binding 
buffer. This procedure was repeated till the whole 35 mL of impure 2E6 antibody 
were passed through the column. To dialyze the purified antibody, the eluted purified 
2E6 antibody solution was concentrated using D³diaflo´XOWUDILOWUDWLRQVWLUUHGFHOO 
(Amicon, 30 kDa; 4oC) to yield a volume of 25 mL and buffer was replaced by adding 
an equal volume of fresh binding buffer and concentrating to half the volume. This 
procedure was repeated 4 times and the volume was finally adjusted to 25 mL.     
  
Since the 2E6 antibody was only partially purified using Protein G Sepharose 
4 Fast Flow (determined using SDS-PAGE [see below]), a second purification step 
was then performed using PD SpinTrap G-25 columns according to manufacturer 
instructions to further purify the 2E6 antibody42. Briefly, 600 µL of binding solution 
(see above) was added while the lower cap was on. The columns were centrifuged 
(Eppendorf 5810R) for 1 min at 825 rpm (after loosening the upper cap and removing 
the lower cap). Then 250 µL of partially purified 2E6 antibody (BCA: 4.2 mg/mL) 
was mixed with 300 µL of binding solution and the mixture was added to the spin 
column while the lower cap was on. Then the upper cap was screwed on and the 
column was mixed by inversion for 8 min. The columns were then centrifuged for 1 
min at 825 rpm and washed twice using binding buffer by adding 600 µL binding 
buffer and centrifuging at 825 rpm for 1 min. Elution was performed twice by adding 
400 µL of elution buffer, mixing by inversion for 1 min and centrifugation (825 rpm 
for 1 min) into collection tubes containing 30 µL of neutralizing solution. The 
columns were reused after washing 5 times with binding solution and storing in 20% 
ethanol at 4oC. The collected solution was then concentrated to half volume using a 
³Centricon´XOWUDILOWUDWLRQV\VWHP kDa; Amicons; 4,000 rpm) and the buffer was 
exchanged by adding equal volumes of binding buffer and concentrating for 5 cycles. 
    
To determine the purity of 2E6 obtained after each purification step, samples 
were analyzed on a 12.5% SDS-PAGE (table 2). The samples were prepared by 
adding an equal volume of sample buffer (2 mL glycerol [Panreac, Germany]; 1 mL 
mercaptoethanol; 5.1 mL 10% SDS; 2.5 mL Tris 0.5 M pH 6.8; 2 mg bromophenol 
blue) and boiling at 100oC for 7 min. Then 20 µL of samples were loaded and run at 
180 mV for 50 min (BIO-RAD; USA). Running buffer used was prepared by diluting 
10X running buffer (30.28 g Tris + 144.13 g glycine + 10 g SDS dissolved in 1 L 
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distilled water) in water. After running the gel, it was stained for 40 min in staining 
solution (0.5% Coomassie blue, 40% methanol, 10% acetic acid [Riedel-de-Haen, 
Germany] in aqueous solution) then destained in destaining solution (45% methanol, 
7.5% acetic acid in aqueous solution) until protein bands were visible. 
  
The concentration of the purified 2E6 antibody was determined by the 
Bicinchoninic Acid (BCA) method. The principle of the BCA assay is that at alkaline 
conditions, Cu2+ (provided in BCA solution B; Sigma, Germany) binds to peptide 
bonds of proteins and amino acids such as cysteine, tryptophan and tyrosine. This 
leads to the reduction of Cu2+ to Cu+.  Cu+ then binds to BCA molecule (provided in 
BCA solution A; Sigma, Germany) forming a complex with an intense purple color, 
the concentration of which  can be determined by spectrophotometry and is 
proportional to the protein concentration43 (figure 6). In our study, zero, 4, 8, 12, 16, 
20, 24 µL of 1 mg/mL bovine serum albumin (BSA; protein standard micro standard, 
Sigma, Germany) were added to 7 tubes as a standard. To 6 other tubes, 10, 10, 20, 
20, 30, 30 µL of 1 : 2 diluted purified 2E6 antibody (in 20 mM phosphate buffer; pH 
= 7.4; sodium phosphate mono and di basic; Riedel-de-Haen, Germany) were added. 
Then 1 mL of BCA mixture (14,706 µL of BCA reagent A + 294 µL of BCA reagent 
B) was added and the solution was mixed by vortexing. The solution was then 
incubated at 37oC for 30 min and absorbance at 562 nm was measured using a UV-vis 
Varian Cary50 spectrophotometer (USA). After determining the concentration of 2E6 
antibody, glycerol was added to give a final concentration of 10%, and the solution 
was aliquoted and stored at -20oC.  
 
3.1.3 Activity of 2E6 antibody 
2E6 mouse monoclonal antibody activity was determined by incubating hepatocytes 
infected with P. berghei with the purified 2E6 antibody. Then AlexaFluor 555-
labelled goat anti-mouse secondary antibody was added, and cell imaging was 
performed using a fluorescence microscope (Leica Microsystems; USA). 
 
3.2   Hsp70 as a diagnostic target 
3.2.1 Western blot analysis of plasma and whole blood of mice infected with P. 
berghei  
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Western blot analysis was performed on plasma and whole blood of mice infected 
with P. berghei using 2E6 as the primary antibody for the detection of PbHsp70 (P. 
berghei heat shock protein 70) antigen. First, a microscopical analysis was performed 
to determine parasitemia level. This was done by making an incision in the mouse tail, 
smearing a blood drop, allowing it to dry, fixing by methanol, leaving to dry, staining 
with Giemsa for 17 - 20 min, finally drying and examining under the microscope. 
 
To perform Western blot analysis, blood was collected from both non-infected 
and P. berghei infected mice. First, mice were sacrificed using CO2, incised to expose 
the heart and the heart was then opened to collect as much blood as possible using a 
tip and a collecting tube wetted with heparin-PBS to prevent blood clotting. Samples 
were then normalized so that the number of RBCs in non-infected and infected blood 
was similar. This was done by calculating the number of RBCs per mL using the 
following equation: 
 
10000uuDFRBCsofnumberAverage  
 
where DF was the dilution factor in PBS. Then the volume of infected and non-
infected blood having the same number of RBCs was withdrawn and each split into 
WZRWKHILUVWQDPHG³ZKROHEORRG´DQGWKHVHFRQG³SODVPD´3ODVPDLVWKH
supernatant left after centrifuging whole blood at 3,000 rpm for 5 min at 4oC. For 
each of the four samples (whole blood and plasma of both infected and non-infected), 
seven 1 : 5 dilutions in PBS were prepared. Equal volume of sample buffer (lamellae 
sample buffer; BIO-RAD, Germany) was added and the samples were heated at 
100oC for 7 min. Then 30 µL of each sample was loaded onto 10% SDS-PAGE (table 
2) and run at 180 mV for 50 min (BIO-RAD). Running buffer was prepared by 
diluting 10X running buffer (30.28 g Tris + 144.13 g glycine + 10 g SDS dissolved in 
1 L distilled water) in water.   
  
 The gel was then blotted onto nitrocellulose membranes by sandwiching the 
gel and a nitrocellulose membrane between 4 filter papers and 2 sponges (sponge/2 
filter papers/gel/nitrocellulose membrane/2 filter papers/sponge) and all these 
components were clamped tightly together, while avoiding air bubbles. The system 
(1) 
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was inserted into transfer buffer and an electrical field (nitrocellulose membrane faces 
positive anode) was applied at 300 mA for 60 min at 4oC (BIO-RAD). Transfer buffer 
(1X) needed for blotting was prepared by diluting 100 mL of 10X stock transfer 
buffer (3.03 g Tris; 14.4 g glycine in 1 L distilled water) with 700 mL water and 200 
mL methanol. After blotting, membranes were washed with 0.05% PBST (250 µL 
Tween on 500 mL PBS) on a shaker at 50 rpm for 5 min. To ensure proper blotting, 
the membranes were stained with Ponceau stain. After the appearance of the protein 
bands, Ponceau stain was washed off using 0.05% PBST at 50 rpm for 5 min. For 
blocking, the membranes were immersed in blocking solution (5% w/v of non-fat dry 
milk in 0.05% PBST) and left overnight (shaken at 18 rpm at 4oC). After blocking, the 
membranes were washed (0.05% PBST; 50 rpm; 5 min) and then reacted with 2E6 
primary antibody (1 : 400; diluted in 5% w/v of non-fat dry milk in PBST 0.05%) for 
1hr (at 18 rpm). Washing 3 times for 5 minutes each using PBST 0.05% (50 rpm) was 
then done and horseradish peroxidase (HRP)-labelled secondary anti-mouse antibody 
(1 : 5,000; diluted in 5% w/v non-fat dry milk in PBST 0.05%) was added and 
incubated for 1 hr (shaken at 18 rpm). Washing was done 3 times for 5 min each using 
PBST 0.05% (50 rpm). Two mL of chemiluminescence substrate (after mixing 1 mL 
of substrate A and 1 mL of substrate B; SuperSignal West Pico Chemiluminescent 
Substrate, ThermoScientific; USA) was finally added to each membrane and left to 
react for 2 min at room temperature. The membrane was then wrapped in a plastic 
sheet and exposed to X-ray film for 2 min. The film was then developed using Curix 
60 from Agfa (USA)44-45.  
 
3.2.2 Western blot analysis of saponin pellets of RBCs of non-infected mice, of 
mice infected with P. berghei, and of non-infected human 
RBCs were separated from whole blood and treated with saponin and the pellet used 
to perform Western blot analysis. Whole blood was centrifuged for 5 min at 3,000 
rpm at 4oC. The plasma was separated and the RBCs were washed twice with PBS 
(centrifuged for 5 min at 3,000 rpm at 4oC). To the RBCs, 1.5 mL of saponin (0.15% 
in PBS) was added and left for 5 min at room temperature with mixing. Then 
centrifugation was performed at 14,000 rpm for 5 min at 4oC. The supernatant was 
UHPRYHGDQGQDPHG³5%&O\VDWH´7KHsaponin pellet was washed with PBS 4 times 
(centrifugation at 13,500 rpm for 5 min at 4oC). The pellet was then resuspended in 50 
µL PBS44. Non-infected human blood was also treated in the same manner, after 
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normalizing for the number of RBCs using the equation 1 (section 3.2.1).  Plasma, 
RBC lysate and saponin pellets samples of non-infected mice, of mice infected with 
P. berghei and of non-infected human were run on SDS-PAGE and Western blot was 
performed as described in detail in section 3.2.1.  
 
3.2.3 Western blot analysis of saponin pellet of RBCs of non-infected mice and of 
mice infected with P. berghei, using actin as loading control 
As a control to the experiments, anti-actin primary antibody and anti-rabbit secondary 
antibody were added as a loading control. Samples were treated with saponin as 
described in section 3.2.2. After running the samples on SDS-PAGE gel and blotting 
and blocking the membranes (see section 3.2.1), membranes were cut just above the 
50 kDa marker band. The upper part of the membrane, was then treated with 2E6 as 
primary antibody and anti-mouse antibody as secondary antibody as described earlier 
(section 3.2.1). The lower part of the membrane was treated with anti-actin antibody 
as primary antibody (1 : 500; diluted in 5% w/v non-fat dry milk in PBST 0.05%) and 
anti-rabbit antibody as secondary antibody (1 : 5,000; diluted in 5% w/v non-fat dry 
milk in PBST 0.05%) 46. The rest of the steps were followed as described in section 
3.2.1. 
 
3.2.4 Western blot analysis of saponin pellet of RBCs of mice blood infected with 
P. berghei and of a human blood culture infected with P. falciparum  
After optimizing Western blot conditions, analysis of human blood culture infected 
with P. falciparum was performed and compared with that of mice blood infected 
with P. berghei. P. falciparum was grown on a continuous culture prepared by 
diluting Albumax II stock solution (25 g Albumax II (Gibco); 0.1 g hypoxanthine; 1 g 
Glucose; 1.67 g NaHCO3; 2.98 g HEPES; 500 µl gentamincin and 5.2 g RPMI 1640 
[with L-glutamine; without NaHCO3]) in 500 mL of RPMI 1640 [no L-glutamine; 
with NaHCO3] and then adding 500 µL gentamycin (50 mg/mL stock), 5 mL of 200 
mM L-glutamine and 12 mL 1 M HEPES. P. falciparum 3D7 (obtained from the 
previous growth) was then grown in a malaria culture medium at a hematocrit of 3 - 
5%. RBCs and leucocytes needed for this culture were separated from buffy coats 
obtained from healthy volunteers by centrifugation using a Ficoll gradient. Both 
samples (human blood culture infected with P. falciparum and mice blood infected 
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with P. berghei) were saponin treated as described in section 3.2.2. Western blot 
analysis followed as described in sections 3.2.1 and 3.2.3 44-46. 
 
3.3   Conjugation of 2E6 antibodies to AuNPs 
3.3.1 Synthesis of AuNPs 
All glassware was soaked with Aqua Regia (HNO3 [Panreac, Germany] and HCl in 
ratio 1 : 3) and left overnight. The next day, glassware was thoroughly rinsed with tap 
water till pH indicator gave pH = 6. The flasks were finally rinsed with Milli-Q water. 
To a 500 mL round bottom flask, 250 mL of HAuCl4 (1 mM; prepared using gold 
(III) chloride solution in dilute HCl, 99.99%, Sigma Aldrich, Germany) were added, a 
condenser was adapted to the flask, and the solution was refluxed with stirring for 1 hr 
(starting from first condensation) using a sand bath. Then 25 mL of sodium citrate 
solution (38.8 mM; Sigma, Germany) were then added. The flask was again left to 
reflux for 15 minutes. Then the solution was allowed to cool and stored in dark until 
further use. The concentration of nanoparticles was determined by UV/vis 
VSHFWURSKRWRPHWU\XVLQJ%HHU¶VODZ(extinction coefficient for the Plasmon band at 
520 nm is 2.33 X 108)47, 48.  
 
 3.3.2 Functionalization of AuNPs with mercaptoundecanoic acid and CALNN 
peptide 
To 30 mL of the AuNP obtained in ³3.3.1´ (concentration 12.7 nM), 45 µL of 
mercaptoundecanoic acid (MUA; Sigma Aldrich, Germany) solution (1 mM in 
ethanol) was added so that the ratio in molarity of MUA to AuNP was 120 (this ratio 
was found to be optimum in previous studies in our lab; section 5.2). The solution was 
mixed and left overnight at 4oC. The concentration was determined the next day as 
described in 3.3.1. Another functionalization was also tested by conjugating a 
CALNN peptide (Cysteine, Alanine, Leucine, Asparagine, Asparagine) which imparts 
a negative charge to the AuNPs, like MUA. AuNPs- CALNN were prepared by Dr. 
3HUHLUD¶VJURXSLQ8QLYHUVLGDGHGR3RUWR. 
 
3.3.3 Conjugation of 2E6 antibodies to AuNP-MUA 
A 2 nM AuNP-MUA solution was prepared from stock solution by diluting with 
Milli-Q water. The pH was adjusted to 7.4 using 0.1 M NaOH (pronalab, Germany). 
Then to 5 mL of AuNP-MUA (2 nM; pH = 7.4), 2E6 antibody was added such that 
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the molar ratio of 2E6 to AuNP-MUA would be 70 (ratio = 70). Then 5 mL of 5 mM 
sodium phosphate buffer (pH = 7) was added. The mixture was mixed and left to 
incubate overnight at 4oC. This allows for the electrostatic binding between 2E6 and 
AuNP-MUA to occur49. In trying to obtain more robust AuNP-2E6 conjugates, 
covalent linkage between 2E6 and AuNP-MUA was also tested through the use of N-
hydroxysuccinimide / 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide 
hydrochloride (NHS/EDC) cross-linkers (NHS: Fluka, Germany). The same 
procedure was used as that for preparing non-NHS/EDC conjugates but instead of 
adding 5 mL of buffer alone (5 mM sodium phosphate buffer; pH = 7), NHS/EDC 
mixture in the same buffer was added. Concentration of NHS and EDC in the 
NHS/EDC mixture was 1.2 mM and 2.8 mM, respectively. The incubation was made 
for 2 hr at room temperature50. Preparation of conjugates was done in glass containers 
to prevent aggregation to the walls of plastic vials. Optimum pH values, ratios of 2E6 
to AuNP-MUA and amounts of NHS/EDC needed for conjugation were all 
determined as described later in 3.4 and 3.5. 
 
3.3.4 Conjugation of 2E6 to AuNP-CALNN 
A 2 nM AuNP-CALNN solution was prepared from stock by diluting in Milli-Q 
water. pH was not adjusted, and then the same protocol as that for MUA particles was 
followed to prepare NHS/EDC linked conjugates. For non-NHS/EDC, sodium 
phosphate buffer (5 mM; pH = 7) was added first (to fix the pH to 7 since no 
adjustment in pH will be done to the AuNP-CALNN), then 2E6 solution and finally 
the AuNP-CALNN solution.  
 
3.4 Characterization of BNCs 
3.4.1 UV-visible spectroscopy 
The first proof of 2E6 antibody conjugation to the AuNPs, was the observation of a 
shift in the absorbance peak maximum to a longer wavelength after 2E6 antibody 
conjugation51. Both NHS/EDC and non-NHS/EDC BNCs were prepared as described 
above (3.3.3). AuNP-MUA (1 nM; pH = 7.4; 1,000 µL) was prepared and 2E6 
antibody was added at a molar ratio of 2E6 to AuNP-MUA of 100 (ratio = 100). Then 
either 500 µL of 5 mM sodium phosphate buffer (pH = 7), to prepare non-NHS/EDC 
BNCs; or NHS/EDC mixture in the same buffer (1.2 mM and 2.8 mM of NHS and 
EDC, respectively), to prepare NHS/EDC BNCs, was added. Non-NHS/EDC 
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conjugates were incubated at 4oC overnight while NHS/EDC conjugates were 
incubated for only 2 hrs at room temperature. After incubation, the absorbance 
spectrum was analyzed.   
 
3.4.2 Agarose gel electrophoresis 
To determine whether or not the conjugates are uniform and non-aggregated, agarose 
gel electrophoresis was used. As a proof-of-concept, BSA BNCs were initially run on 
the gel. AuNP-MUA (5 nM) was prepared by diluting stock with Milli-Q water and 
pH was adjusted to 7.4 using 0.1 M NaOH. Different molar ratios of BSA to AuNP-
MUA (1,000 µL) were prepared ranging from 0 - 4,000. To the mixture, 500 µL of 5 
mM sodium phosphate buffer (pH = 7) was added and the volumes of the different 
ratios were made equal by adding the appropriate amount of buffer. After incubating 
the BNCs overnight at 4oC, glycerol was added to the BNCs to a final concentration 
of 10% and 30 µL of the samples were loaded onto 1% agarose gel (ultra pure 
agarose, Invitrogen, Germany) prepared in sodium phosphate buffer (5 mM; pH = 7). 
Running buffer used was also sodium phosphate buffer (5 mM; pH = 7) and the 
electrophoresis was run at 70 mV (BIO-RAD; USA) 52. 
 
After proof-of-concept of agarose gel electrophoresis using BSA non-
NHS/EDC conjugates, 2E6 BNCs (with or without NHS/EDC) were prepared and run 
on agarose gel electrophoresis after determining the optimum amount of NHS/EDC 
needed for cross linking. To determine the optimum amount of NHS/EDC mixture 
needed for cross linking, different concentrations of NHS/EDC were prepared 
(concentration in NHS/EDC mixtures were: 0.6 mM and 1.4 mM; 1.2 mM and 2.8 
mM; 3 mM and 7 mM; 6 mM and 14 mM of NHS and EDC, respectively). The 
concentration of AuNP-MUA used for preparing NHS/EDC BNCs was 1 nM and the 
pH was adjusted at 7.4 (2,000 µL). The molar ratio of 2E6 to AuNP-MUA was 250 
and 1,000 µL of the different mixtures of NHS/EDC (0.6 mM and 1.4 mM; 1.2 mM 
and 2.8 mM; 3 mM and 7 mM; 6 mM and 14 mM of NHS and EDC, respectively) 
were then added. The BNCs were incubated at room temperature for 2 hrs then 
centrifuged at 7,000 rpm for 10 min. The supernatant (light pink in color) was 
removed to get rid of most of unconjugated 2E6 and the pellet was resuspended in 
1,000 µL Milli-Q water. The solution was then concentrated using ³Centricons´ 
(Amicon, 30 kDa; centrifuged at 4,000 rpm) ultrafiltration system, for a final volume 
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of 50 µL. This concentration step was done to enhance color to be easily seen on the 
gel. Glycerol (final concentration 10%) was then added and samples were run on 1% 
agarose gel at 70 mV. 
 
After optimizing the concentration of NHS/EDC, concentration of 1.2 mM and 
2.8 mM of NHS and EDC, respectively, was chosen since it was the highest 
concentration that prepared stable, uniform and non-aggregated conjugates. 
Concentration of 0.6 mM and 1.4 mM of NHS and EDC, respectively, also produced 
stable conjugates but we preferred the 1.2 mM and 2.8 mM concentration to ensure 
that the concentration was not too low and that the reaction was complete. Conjugates 
with different molar ratios (from 5 - 70) of 2E6 to AuNP-MUA were prepared in the 
presence and absence of NHS/EDC. In this study, AuNP-MUA (2 nM; pH = 7.4; 
2,000 µL) was used. Milli-Q water was used to make the volumes equal for 
conjugates with different ratios of 2E6 to AuNP-MUA. For non-NHS/EDC 
conjugates, 2,000 µL of buffer was added while for NHS/EDC conjugates a mixture 
of NHS/EDC (1.2 mM and 2.8 mM of NHS and EDC, respectively; 2,000 µL) was 
added. Conjugates were left to incubate (overnight at 4oC for non-NHS/EDC and 2 
hrs at room temperature for NHS/EDC conjugates). After incubation, conjugates were 
centrifuged at 6,000 - 7,000 rpm for 10 min and the pellet remaining after supernatant 
removal was resuspended in minimal volume of the remaining solution. Glycerol 
(final concentration 10%) was added and samples were run on 1% agarose gel at 70 
mV. 
 
For AuNP-CALNN particles, the optimum NHS/EDC concentration was also 
determined by the same procedure used for AuNP-MUA. Different concentrations of 
NHS/EDC were prepared (buffer only; 0.3 mM and 0.7 mM; 0.6 mM and 1.4 mM; 
1.2 mM and 2.8 mM; 3 mM and 7 mM of NHS and EDC, respectively). The 
concentration of AuNP-CALNN used was 2 nM (2,000 µL) and the molar ratio of 
2E6 to AuNP-CALNN was 100. To the mixtures, 2,000 µL of the different NHS/EDC 
concentrations was added. The BNCs were incubated at room temperature for 2 hrs 
for NHS/EDC conjugates but overnight incubation at 4oC was performed for non-
NHS/EDC conjugates. After incubation, conjugates were centrifuged at 7,000 rpm for 
10 min. Supernatants were removed and pellets were resuspended in minimal volumes 
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of the remaining solution. Glycerol (final concentration 10%) was then added and the 
samples were run on 1% agarose gel at 70 mV. 
 
3.4.3 Zeta (ȗ)-potential 
Non-NHS/EDC BNCs with different molar ratios (0 - 400) of 2E6 to AuNP-MUA 
were prepared (final concentration of AuNP-MUA 1 nM; pH = 7.4). Milli-Q water 
was used to make the volumes equal for conjugates with different ratios of 2E6 to 
AuNP-MUA. It is important to note that before diluting 2E6 antibody with 20mM 
sodium phosphate buffer (pH = 7.4), the buffer was filtered using a syringe disc filter 
(0.45 µm; Whatman, nylon 0.45 µm pore diameter, Germany). For NHS/EDC BNCs, 
the same ratios of 2E6 to AuNP-MUA were prepared to allow the comparison 
between non-NHS/EDC and NHS/EDC BNCs. AuNP-MUA (final concentration 1 
nM; pH = 7.4) was used. Milli-Q water was also used to make the volumes equal for 
conjugates with different ratios of 2E6 to AuNP-MUA. Concentration of 1.2 mM and 
2.8 mM of NHS and EDC, respectively, was used and the mixture was filtered using a 
syringe disc filter (0.45 µm) before use. Instead of adding 525 µL of the NHS/EDC 
solution (1.2 mM and 2.8 mM of NHS and EDC, respectively) to the BNCs, only 350 
µL was added. Although adding 525 µL of the NHS/EDC to the BNCs would have 
allowed the optimum amount of NHS/EDC to be added (see sections 3.4.2 and 4.4.2), 
it could have led to the aggregation of BNCs having low molar ratios of 2E6 to 
AuNP-MUA. Thus it was decided to add a lower amount of NHS/EDC (equivalent to 
using 0.78 mM and 1.82 mM of NHS and EDC, respectively). This was also 
supported by the fact that a concentration as low as 0.6 mM and 1.4 mM of NHS and 
EDC, respectively, was proven to be as effective as the concentration of 1.2 mM and 
2.8 mM of NHS and EDC, respectively (section 4.4.2). After incubating all BNCs 
overnight, ȗ-potential was measured. 
 
ȗ-potential measurements were performed in a Zetasizer Nano-ZS from 
Malvern Instruments. A 4 mW He-Ne laser (633 nm) was used with a fixed 173 º 
'/6RUȗ-potential) scattering angle. All measurements were carried out at 
25ºC. The zeta cell and caps were cleaned with Milli-Q water. One mL of sample was 
loaded into the disposable ȗ-potential cuvette. The caps were then fitted and the cell 
was inserted into the machine. The software was adjusted as follows: Material: 
protein; dispersant: water; temperature: 25oC; equilibration time: 900 sec; 
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measurement: monomodal; number of measurements: 4; number of runs: 100. 
Between samples, the cell was cleaned with at least 60 mL of Milli-Q water53.  
 
3.5   Stability of AuNP-MUA-2E6 conjugates 
3.5.1 NaCl method 
Both NHS/EDC (1.2 mM and 2.8 mM of NHS and EDC, respectively) and non-
NHS/EDC BNCs with different molar ratios (0 - 70) of 2E6 to AuNP-MUA (2 nM; 
pH = 7.4; 2,000 µL) were prepared as described earlier (section 3.4.2). The conjugates 
were then centrifuged at 7,000 rpm for 10 min. The supernatant was removed and the 
pellet was resuspended in minimal volume of the remaining solution. Then to 30 µL 
of samples, 30 µL of 5 M NaCl (Panreac, Germany) were added at room temperature 
and left for 6 hrs. Visible absorbance spectra were then performed to determine the 
least amount of 2E6 antibody required to stabilize the BNCs against 5 M NaCl 54.    
 
3.5.2 pH aggregation 
The pH of 1 nM AuNP-MUA was changed using 0.1 M HCl or 0.1 M NaOH and the 
absorbance spectra were analyzed using visible spectroscopy. The same was done to 
non-NHS/EDC and NHS/EDC 2E6 BNCs. Five mL of AuNP-MUA (2 nM) were 
prepared and pH was adjusted to 7.4. Then to each of 2.5 mL of AUNP-MUA, 2E6 
monoclonal antibody was added to give a molar ratio of 2E6 to AuNP-MUA of 70. 
Then 2.5 mL of either buffer (5 mM sodium phosphate buffer; pH = 7) or NHS/EDC 
mixture (1.2 mM and 2.8 mM of NHS and EDC, respectively) was added to prepare 
non-NHS/EDC and NHS/EDC BNCs, respectively. Incubation was performed 
overnight at 4oC. It is important to note that the final concentration of AuNP-MUA in 
the BNCs was 1 nM allowing the comparison with naked AuNP-MUA particles (also 
1 nM). The next day, pH of the conjugates was first decreased (using 0.1 M HCl) and 
then increased (using 0.1 M NaOH) on the same tube and absorbance was measured 
at different pH values (ranging from 1 - 11) 55.      
 
3.6   PfHsp70 expression 
3.6.1 Transformation of pQE30/PfHsp70 into RosettaBlue cells 
Two hundred nanograms of pQE30/PfHsp70 plasmid, harbouring the PfHsp70 gene, 
were kindly provided by Prof. Gregory Blatch (Rhodes University, South Africa) in a 
paper dried drop format. The paper dried drop was submersed in 20 µL of autoclaved 
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water to give a final concentration of 10 ng/µL. Two µL of either pQE30/PfHsp70 
plasmid (10 ng/µL), positive control (³7HVt Plasmid´supplied with cells) or 
autoclaved water (for negative control) were added to 20 µL RI5RVHWWD%OXHFHOOV 
(Novagen; 71058-4). Cells were then put on ice for 30 min before transformation by 
heat shock. The ice cold tubes were heated for 45 sec at 42oC then placed on ice for 2 
min. After heat shock, ȝO SOC solution (supplied with cells) was added to each of 
the three tubes and the cells were incubated at 37°C for 60 min. SOC is a mixture of 2 
g tryptone, 0.55 g Yeast extract, 1 mL 1 M NaCl, 0.25 mL 1 M KCl and 97 mL water 
that is autoclaved and cooled and to which 1 mL 1 M MgCl2; 1 mL 1 M MgSO4 and 1 
mL 2 M glucose is added. Cells were then plated onto Luria Broth (LB) agar plates 
having both ampicillin and chloramphenicol with final concentrations of 100 µg/mL 
and 34 µg/mL, respectively; and left overnight to grow at 37oC. Colonies on the plate 
were detected the next day indicating transformed cells56-57.  
  
To generate a transformant stock solution, colonies were inoculated in LB 
liquid media having both chloramphenicol and ampicillin (same ratio as plates) and 
incubated overnight at 37oC allowing further bacterial growth. A negative control was 
performed substituting the cells with autoclaved water, to check for contaminations. 
The grown cells were then stocked in 30% glycerol at -80 ºC until further use. For 
expression studies, the stocked cells were streaked onto LB agar plates (containing 
chloramphenicol and ampicillin) and selected colonies were grown as described in the 
following section.  
 
3.6.2 Expression of PfHsp70 under different induction conditions 
For expression of PfHsp70, first a 50 mL preinoculum was prepared from which a 
larger culture (250 mL) was prepared. The 50 mL LB preinoculum (0.5 g 
bactotryptone [BD, Germany]; 0.25 g bactoyeast [BD, Germany]; 0.5 g NaCl; 
complete to 50 mL distilled water) contained 100 µL ampicillin (100 µg/mL), 125 µL 
of tetracycline (12.5 µg/mL) and 50 µL of chloramphenicol (34 µg/mL) plus a colony 
of transformed cells. Another flask was prepared as a blank having everything except 
the colony of transformed cells. After overnight incubation (210 rpm; 37oC), blank 
was clear and the other flask was turbid from which 2.5 mL was added into each of 
three flasks having 250 mL fresh media having the same ratio of antibiotics. Flasks 
ZHUHQDPHG³QR,37*´³,37*KU´DQG³,37*RYHUQLJKW´ It is important to note 
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that aseptic conditions were followed throughout the transformation and expression 
procedures, including autoclaving the flasks, autoclaving the media before adding 
antibiotics and doing inoculations near a flame. The flasks were then incubated at 
37oC at 210 rpm. For each flask, 0.5 mL was withdrawn aseptically every 30 min until 
an optical density at 600 nm (O.D600) reached 0.5 - 0.6. No addition was made to the 
flask labelled ³QR,37*´ and harvesting was done the following day. To the flask 
labelled ³,37*KU´mL of 0.1 M ,VRSURS\Oȕ-D-1-thiogalactopyranoside (IPTG) 
was added and cells were further incubated for 2 hrs (210 rpm; 37oC) before 
harvesting)RU³,37*RYHUQLJKW´mL of 0.1M IPTG was added and incubation 
was done overnight (210 rpm; 37oC) and cells were harvested the next day. For 
harvesting, a sample was withdrawn to determine final O.D600 value and medium 
centrifuged at 10,000 rpm for 30 min. The supernatant was discarded and the pellet 
was weighed and then resuspended in lysis buffer (8 M urea [Panreac, Germany], 300 
mM NaCl, 10 mM imidazole, 10 mM Tris pH 8.0, 1 mM phenyl methyl sulphonyl 
fluoride, and 1 mM lysozyme). 7KH³QR,37*´ flask pellet was resuspended in 10 
mL; the ³,37*KU´pellet was resuspended in 4 mL and the ³,37*RYHUQLJKW´pellet 
was resuspended in 6 mL. The resuspended pellets were then frozen at -20oC. Pellets 
obtained from cultures under different induction conditions were run on 10% SDS-
PAGE, followed by Western blot analysis using 2E6 as primary antibody 57. As a 
control, a 50 mL inoculum was prepared using the same protocol (same ratio of 
antibiotics as for the pre-inoculum) but using non-transformed 5RVHWWD%OXH cells 
instead of transformed ones 57. 
 
3.6.3 Expression of PfHsp70 under optimum conditions in a large scale 
Eight flasks of 250 mL bacterial cultures were fermented, IPTG was used for 
induction of protein over-expression, and harvesting was done the following day. 
Instead of PMSF in lysis buffer, a protease inhibitor cocktail was used to reduce 
PfHsp70 degradation. This protease inhibitor cocktail solution was prepared by 
dissolving complete Protease Inhibitor Cocktail tablet (Roche Applied Science; 11 
697 498 001) in 2 mL of Milli-Q water57-58. After harvesting, the total pellet was 
resuspended in 20 mL of lysis buffer which contained 800 µL of protease inhibitor 
cocktail solution.    
 
3.7   Purification of PfHsp70 using Ni-NTA column 
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Since the expressed PfHsp70 has a 6xHis-tag at its N-terminus, Ni-NTA column was 
used as the method for its purification from the bacterial crude extract. The total 
resuspended pellet produced from the eight 250 mL culture flasks (20 mL) was 
thawed and homogenized by a homogenizer. Then a small amount of DNAse (Roche, 
Germany) was added to reduce viscosity before cell breakage by French-press. 
Bacteria were then lysed by passing the solution through a French pressure cell press 
(Thermo; Germany) at 2,000 psi gauge pressure (about 30,000-35,000 psi cell 
pressure). Pressure was applied three times to ensure cell destruction. Following cell 
lysis by French press, the solution was centrifuged at 5,000 rpm for 90 min to remove 
cell debris (pellet). To the supernatant, 25 µL of 10 mg/mL PMSF (in propanol) was 
added. Then 5 mL of Ni-NTA agarose (Qiagen; 30210) that was previously 
equilibrated with 60 mL lysis buffer (without lysozyme or PMSF) was mixed with 
supernatant at 4oC for 2 hr. The solution was loaded onto column support and the 
solution passing through the column ZDVQDPHG³IORZWKURXJK´)7Column 
washing was performed to remove non-specifically bound proteins, leaving only 
strongly bound proteins (those having His-tag) attached to the column. The washing 
buffer used was 300 mM NaCl, 10 mM imidazole, and 10 mM Tris (pH 8.0). 
Washing was continued till absorbance at 280 nm was lower than 0.1, assuring that no 
appreciable amount of protein material was present in the washes. PfHsp70 was then 
eluted from the column using 300 mM NaCl, 100 mM imidazole, and 10 mM Tris 
(pH 8.0) and the elute was collected till absorbance (at 280 nm) was lower than 0.157. 
The eluted solution was then concentrated using 30 kDa ³Centricon´XOWUDILOWUDWLRQ
system (Amicon; 4,000 rpm) and buffer was exchanged by adding an equal volume of 
borate buffer (0.1 M borate pH = 8.3; 150 mM NaCl) and concentrating to half 
volume. This procedure was repeated 4 times. SDS-PAGE (10%) and BCA analysis 
were then performed to determine the purity and concentration of PfHsp70, 
respectively.   
 
 3.8   Labelling of PfHsp70 with Cy3B 
For the fluorescence quenching competitive immunoassay, PfHsp70 needs to be 
labelled with Cy3B. Cy3B (1 mg; GE Healthcare; Germany) was dissolved in 200 µL 
Dimethyl sulfoxide (DMSO) to make a solution of 5 mg/mL. From this Cy3B 
solution, 5.1 µL were added to 710 µL of purified PfHsp70 (1.74 mg/mL; or 24 
nmol/mL; section 3.7). This led to a molar ratio of Cy3B to PfHsp70 of 2 : 1. The 
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reaction was mixed in dark for one hour. To stop the reaction, 84.2 µL lysine (0.19 
M) was added to give a final concentration of lysine of 0.02 M 39,59. The reaction was 
mixed for an additional 10 min in dark. To remove most of lysine and the free 
unreacted excess dye, the solution was concentrated using ³Centricons´ (30 kDa; 
Amicon; 4,000 rpm) to half the volume. Then an equal volume of buffer (0.1 M 
borate pH = 8.3; 150 mM NaCl) was added. The solution was concentrated again and 
this procedure was repeated 4 - 6 times till the filtrate became nearly colorless to 
slightly pink. The solution was finally concentrated to 800 µL and absorbance 
spectrum was run and compared with spectrum of free Cy3B. The solution of labelled 
antigen was aliquoted and stored at -20oC.   
 
3.9   Chip assay 
A chip assay was developed to prove that the activity and specificity of 2E6 was not 
affected by conjugation with AuNP-MUA (with or without NHS/EDC) and to 
determine whether the cross-linked or the non-cross-linked conjugate is more active, 
based on the intensity of the red color produced on the strips after normalization 
between both conjugates. A proof-of-concept of competitive chip assay was also 
performed.  
 
First, BNCs (with or without NHS/EDC) for chip assay were prepared and 
pre-incubated with either buffer (as blank sample) or PfHsp70 solution (as a positive 
sample). NHS/EDC conjugates were prepared as described previously in section 3.3.3 
(10 mL of 2 nM AuNP-MUA; molar ratio = 70; 1.2 mM and 2.8 mM of NHS and 
EDC, respectively) then centrifuged (7,000 rpm for 10 min) and the pellet was 
resuspended in 400 µL of 10 mg/mL BSA (in 0.1 M borate pH = 8.3; 150 mM NaCl) 
and left for 1hr, then centrifuged again and resuspended in 250 µL BSA. Then to half 
of these conjugates (125 µL), 100 µL concentrated PfHsp70 solution (1.74 mg/mL; 
obtained from section 3.7) was added (positive sample) and to the other half, 100 µL 
buffer (0.1 M borate pH = 8.3; 150 mM NaCl) was added (blank). Non-NHS/EDC 
conjugates were prepared as described previously in section 3.3.3 (10 mL of 2 nM 
AuNP-MUA; molar ratio = 70; buffer alone added instead of NHS/EDC); then the 
conjugates were centrifuged and pellet resuspended in 400 µL of 10 mg/mL BSA and 
left for 1hr, then centrifuged again and resuspended in 250 µL BSA, as in the case of 
NHS/EDC conjugates. To normalize samples, absorbance at peak maximum (530 nm) 
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of non-NHS/EDC conjugates was compared to that of NHS/EDC conjugates and thus 
the former conjugates were diluted (absorbance of NHS/EDC: 1.107; non-NHS/EDC: 
1.226). From the 250 µL of non-NHS/EDC conjugates, 203 µL were pipetted and 
diluted to 250 µL by adding 47 µL of 10 mg/mL BSA. Thus now both the 
concentration and the volume of the two conjugates were exactly the same, allowing 
comparison between the two. Again to half of these conjugates (125 µL), 100 µL 
concentrated PfHsp70 (1.74 mg/mL) was added (positive sample), and to the other 
half, 100 µL buffer (0.1 M borate pH = 8.3; 150 mM NaCl) was added (blank). After 
adding the buffer or the PfHsp70 protein to either NHS/EDC or non-NHS/EDC 
conjugates, solutions were incubated for 1hr at room temperature. 
  
To perform the chip assay, PfHsp70 antigen (7 µL of 1.74 mg/mL; section 
3.7) was added to each of the 4 nitrocellulose strips as a drop. Then 3.5 µL of control 
non-transformed RosettaBlue cells (pellet produced from 50 mL culture, 
resuspended in lysis buffer; see section 3.6.2) was added to the opposite end of the 
nitrocellulose strips. Strips were allowed to dry for 1 hr at room temperature and then 
blocked by soaking in blocking solution (0.25 g of non-fat dry milk in 5 mL PBT [see 
below]). Blocking was performed for 1hr at room temperature. The strips were then 
washed once by soaking in PBT (50 mM phosphate buffer; 0.05% tween) for 2 min, 
and then the different conjugates (non-NHS/EDC or NHS/EDC preincubated with 
either buffer or pure PfHsp70) were added and incubated for 1 hr. After incubation, 
the strips were washed with PBT (for 15 min) and a photo was taken using a regular 
digital camera (Nikon) 54,60.  
 
3.10  Fluorescence quenching competitive assay 
As a proof-of-concept, AuNP-MUA particles were added to determine their 
quenching effect over Cy3B-labelled PfHsp70. To 193 µL of borate buffer (0.1 M 
sodium borate pH = 8.3; 150 mM NaCl), 7 µL of 1 : 25 dilution of Cy3B-PfHsp70 
stock (see section 3.8; 1 : 714 dilution from stock) was added. Then 200 µL of AuNP-
MUA was added to give a final concentration ranging from 0 - 2.75 nM (table 3). 
After the addition of AuNP-MUA, fluorescence emission was measured immediately 
using luminescence spectrometer LS45, Perkin Elmer (excitation wavelength 480 
nm). Standard deviation of fluorescence emission values at 572 nm was 0.26 as 
determined by measuring buffer alone 4 times.  
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The fluorescence quenching competitive assay was developed for the 
detection of PfHsp70. In positive samples, PfHsp70 in borate buffer [0.1 M borate pH 
= 8.3; 150 mM NaCl] was pre-incubated with AuNP-MUA-2E6 and this mixture was 
added to Cy3B-labelled PfHsp70. Since the 2E6 is partially/fully saturated by 
unlabelled PfHsp70, binding to labelled antigen was inhibited and thus fluorescence 
was less quenched giving a high intensity value. In case of blank, the same procedure 
was followed but buffer was pre-incubated with AuNP-MUA-2E6 instead of PfHsp70 
before adding to Cy3B-labelled PfHsp70. Thus the 2E6 binding sites were free (not 
bound to unlabelled antigen) and were thus able to bind to labelled antigen. 
Quenching occurred and fluorescence intensity was low (figure 5). In this experiment, 
for preparing BNCs, 29.5 mL of AuNP-MUA-2E6 (2 nM) was prepared and the 
molar ratio of 2E6 to AuNP-MUA was 70. No NHS/EDC mixture was added (since 
non-NHS/EDC BNCs are more active: see section 4.9). The conjugates were 
centrifuged at 7,000 rpm for 10 min and the pellet was resuspended in 600 µL BSA 
(10 mg/mL in borate buffer). The conjugates were incubated for 1 hr and then 
centrifuged at 7,000 rpm for 10 min and the pellet was resuspended in 600 µL borate 
buffer. The conjugates were centrifuged again at 7,000 rpm for 10 min and finally 
resuspended in 300 µL of borate buffer. 
 
Two tubes were prepared for each sample. In tube 1, 193 µL borate buffer [0.1 
M borate pH = 8.3; 150 mM NaCl]) was mixed with 7 µL of Cy3B-PfHsp70 (1 : 25). 
This was the same for all samples. In tube 2, 10 µL of AuNP-MUA-2E6 was mixed 
with different concentrations of PfHsp70 (final concentration of 8.7 µg/mL; 870 
ng/mL; 87 ng/mL; 8.7 ng/mL; 870 pg/mL) and the volume was completed to 200 µL 
with borate buffer. After incubating tube 2 for 1 hr at room temperature, tubes 1 and 2 
were mixed and fluorescence emission was measured immediately (excitation 
wavelength 480 nm). Standard deviation of fluorescence emission values at 574 nm 
was 0.67 as determined by measuring buffer alone 4 times 39.  
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CHAPTER 4. RESULTS 
4.1  Production, purification and activity of anti-PfHsp70 antibody (2E6)  
From 2.6 L hybridoma culture, 35 mL of concentrated impure 2E6 solution was 
obtained (60 mg/mL of total protein as determined using BCA test). Purification of 
antibody was performed in two steps, namely (i) Protein G Sepharose 4 Fast Flow; 
and (ii) PD SpinTrap G-25 columns. 2E6 obtained from Protein G Sepharose 4 Fast 
Flow was only partially purified as determined by SDS-PAGE (fig. 7). The reason for 
that might be that the protein G Sepharose 4 Fast Flow method needed further 
optimization, such as increasing the number of washes before elution. When the 
partially purified 2E6 was further purified using PD SpinTrap G-25 spin columns, 
pure 2E6 was obtained (fig. 7). The two bands on SDS-PAGE had calculated 
molecular weights of ~31 kDa and ~58 kDa, based on a calibration curve constructed 
with the migration distances of molecular markers (figure 8). After each batch 
purification of 2E6 using PD SpinTrap G-25 columns, the protein concentration was 
determined using BCA test. An example of one of the BCA results for the purified 
2E6 antibody is shown in table 4 (concentration is 20.9 µM) and the standard curve is 
shown in figure 9. Regarding the activity of 2E6 antibody, fluorescence microscopy 
showed that 2E6 antibody was active.  
 
4.2   Hsp70 as a diagnostic target 
Since the present study involved the development of prototype immunoassays, the 
specific recognition of Hsp70 target in a clinical specimen by 2E6 had to proven. This 
was performed by Western blot analysis using 2E6 as the primary antibody. 
      
4.2.1 Western blot analysis of plasma and whole blood of mice infected with P. 
berghei  
Parasitemia (percentage of parasite-infected RBCs / 100 counted RBCs) was around 
5% in all experiments (Dr.Claudia Sa e Cunha, PhD; Personal communication). 
Western blot analysis was performed using 2E6 antibody as the primary antibody for 
the detection of PbHsp70 in plasma and whole blood of mice infected with P. 
berghei. No difference was found when comparing plasma of P. berghei infected and 
non-infected blood (fig. 10). However, in the case of whole blood analysis, infected 
mice blood had an additional band at about 75 kDa (as expected for the presence of 
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PbHsp70) (fig. 11). Thus PbHsp70 seems not to be secreted into plasma but to be 
confined within the infected RBCs. Since several bands still appear in the negative 
whole blood sample, the antibody seems to bind non-specifically to other proteins that 
are mainly present in plasma, as can be concluded from the observation of the same 
bands in negative whole blood and in negative plasma. To overcome this drawback, 
RBCs were separated from whole blood and treated with saponin and the pellet after 
saponin treatment was compared between non-infected and infected samples. Saponin 
causes the rupture of RBCs and the release of RBC cytoplasmic content into lysate 
(supernatant). Plasmodium Hsp70 is localized within the parasitic membrane and is 
not exported into the RBC cytoplasm and thus should not be found in the lysate but 
should be seen in the pellet44. 
 
4.2.2 Western blot analysis of saponin pellets of RBCs of non-infected mice, of 
mice infected with P. berghei, and of non-infected human 
RBCs of non-infected human, and of mice infected or non-infected with P. berghei, 
were treated for 5 min with saponin. Saponin pellets were then compared using 
Western blot analysis and as expected a band corresponding to PbHsp70 was only 
found in the infected RBCs lanes and not in the non-infected mice and human (fig. 
12). Interestingly, no bands were detected in the non-infected human RBC saponin 
pellet even if undiluted. As a control to the experiments, actin was then used as a 
loading control. Actin is a protein that is present in RBC skeleton and thus if the same 
number of RBCs were lysed by saponin and loaded onto the SDS-PAGE, in case of 
non-infected mice and mice infected with P. berghei, the intensity of the band 
corresponding to actin should be similar61. Even when the bands of actin were of 
comparable intensity (RBC normalization was achieved), the non-infected mice RBC 
saponin pellet did not show a band corresponding to PbHsp70 while this band was 
present in the infected mice RBC saponin pellet (fig. 13). 
 
4.2.3 Western blot analysis of saponin pellet of RBCs of mice blood infected with 
P. berghei and of human blood culture infected with P. falciparum  
After establishing the proof-of-concept of using 2E6 to specifically recognize 
PbHsp70 in saponin pellet of RBCs of mice infected with P. berghei, recognition of 
PfHsp70 in P. falciparum infected human blood culture was tested as this system 
more closely mimics the human application of the immunoassays that are being 
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developed. As expected, the actin band intensities of saponin pellets of RBCs of mice 
blood infected with P. berghei and human blood culture infected with P. falciparum 
were similar (since they were normalized). The band intensity corresponding to 
PfHsp70 was much stronger than that of PbHsp70 indicating that 2E6 binds more to 
PfHsp70 than PbHsp70, as expected (fig.14).  
 
4.3   AuNP synthesis and functionalization with MUA 
The procedure followed for the synthesis of AuNPs produced nanoparticles of an 
average diameter of 17 nm. This was determined in a previous study using 
Transmission Electron Microscopy (TEM)47. Inductive Coupled Plasma (ICP) was 
used in a previous study for proof of functionalization of AuNP with MUA by the 
simultaneous detection of gold and sulphur62.   
 
4.4   Characterization of BNCs 
4.4.1 UV-visible spectroscopy 
As a proof of conjugation of AuNP-MUA with 2E6 to generate BNCs, absorbance 
spectroscopy was performed. 2E6 conjugation was clearly proven by a significant 
shift in plasmon resonance peak maximum to a longer wavelength, from 521 nm to 
530 nm (figure 15). 
 
4.4.2 Agarose gel electrophoresis  
As a proof-of-concept, BSA BNCs were prepared with different ratios of BSA to 
AuNP-MUA and were run on agarose gels (figure 16). AuNPs-MUA and AuNPs- 
citrate aggregated in the wells possibly due to surface charge cancellation caused by 
the running buffer (5 mM sodium phosphate buffer; pH = 7). Since BSA conjugates 
carry a net negative charge (as determined by ȗ-potential in a previous study 
performed in our lab), they should migrate towards the positive pole. It could be 
observed on the gel (figure 16) that as the molar ratio of BSA to AuNP-MUA 
increases, implying a larger size of the conjugate formed, the conjugate shows 
retarded migration on the gel. After proof-of-concept, 2E6 conjugates were prepared, 
with or without NHS/EDC, to determine which of the conjugates are more uniform 
and robust. First, the optimum concentration of NHS/EDC required for cross-linking 
was determined by preparing BNCs using different concentrations of NHS/EDC as 
described in detail under method section (3.4.2). After running samples on 1% 
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agarose gel, it was found that both 0.6 mM; 1.4 mM and 1.2 mM; 2.8 mM of NHS 
and EDC, respectively, were equally suited for preparing stable, uniform and non-
aggregated conjugates (figure 17). Thus concentration of 1.2 mM and 2.8 mM of NHS 
and EDC, respectively, was chosen for further studies since it was the highest 
concentration of NHS/EDC to produce stable uniform conjugates. In case of 
concentration of 6 mM and 14 mM of NHS and EDC, respectively, it was clear that 
the BNCs were aggregated in the wells. BNCs with different 2E6 to AuNP-MUA 
molar ratios were then prepared with NHS/EDC (1.2 mM and 2.8 mM of NHS and 
EDC, respectively) or without NHS/EDC. After agarose gel electrophoresis, it could 
be noted that bands for the NHS/EDC conjugates were slightly more compact (figure 
18), indicating that, as expected, NHS/EDC conjugation produced more uniform and 
robust AuNP-MUA-2E6 conjugates.  
 
For AuNP-CALNN particles, the optimum NHS/EDC concentration was also 
determined by gel electrophoresis. NHS/EDC BNCs prepared using concentration of 
3 mM and 7 mM of NHS and EDC, respectively, was found to be the most stable and 
uniform as seen as a compact band compared to conjugates prepared without or with 
other concentrations (ranging from 0.3 - 1.2 mM and 0.7 - 2.8 mM of NHS and EDC, 
respectively). See figure 19.   
 
4.4.3 Zeta (ȗ)-potential 
Both non-NHS/EDC and NHS/EDC BNCs were prepared (AuNP-MUA 1 nM; molar 
ratios = 0 - 400; 0.78 mM and 1.82 mM of NHS and EDC, respectively [for 
NHS/EDC BNCs]) and ȗ-potential measured.The ȗ-potential for non-NHS/EDC 
BNCs showed an increase in ȗ-potential with the increase in 2E6 to AuNP-MUA 
molar ratios till a ratio of about 70 where the ȗ-potential was stabilized suggesting the 
stabilization of the number of antibodies that bind to the AuNP-MUA (figure 20). The 
binding constant for the conjugation process was determined to be KL = 0.023, by the 
fitting of a Langmuir-type curve to the experimental data (equation 2). 
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LQZKLFKǻȗLVWKHYDULDWLRQLQWKHȗ-potential measured for a certain 
[2E6]/[AuNP-MUA] in relation to AuNP-MUAǻȗPD[LVWKHPD[LPXPYDOXHIRU
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ǻȗ-potential as [2E6]/[AuNP-MUA] increases and KL is a binding constant 
corresponding to the value of the inverse of the concentrations ratio, for one-half of 
ǻȗPD[For the NHS/EDC BNCs, the ȗ-potential increase was sharper, i.e., the 
binding constant for antibody binding was higher (KL = 0.161). This behavior is 
expected since NHS/EDC cross-linking contributes to a tighter conjugation, thus 
BNCs can be totally covered with antibody with lower amounts of antibody than their 
non-crosslinked counterparts. In other words, NHS/EDC helps more antibody to be 
conjugated to the AuNP-MUA for conjugates having low 2E6 to AuNP-MUA molar 
ratios. The ȗ-potential plateau value for NHS/EDC BNCs was 30. At high 2E6 to 
AuNP-MUA molar ratios, more 2E6 antibodies seemed to bind to AuNP-MUA when 
no NHS/EDC cross-linking agent was present, as can be observed by the higher ȗ-
potential plateau value for the non-NHS/EDC samples. 
 
4.5   Stability of AuNP-MUA-2E6 BNCs 
4.5.1 NaCl method 
To determine the minimum amount of 2E6 that is necessary to stabilize the BNCs, an 
equal volume of 5 M NaCl was added to the BNCs and the absorbance was measured 
after 6 hrs to allow time for aggregation to occur. As shown by the absorbance spectra 
(figures 21 and 22), the minimum molar ratio of 2E6 to AuNP-MUA to stabilize 
against 5 M NaCl for both non-NHS/EDC and the NHS/EDC conjugates was 20. 
NHS/EDC conjugates seemed to be slightly more stable against 5 M NaCl than non-
NHS/EDC conjugates (for molar ratios  15), as expected. 
 
4.5.2 pH aggregation 
AuNP-MUA nanoparticles (1 nM) were aggregated at pH  4 (figure 23). 2E6 BNCs 
with or without NHS/EDC were prepared (final AuNP-MUA concentration 1 nM; 
molar ratio = 70; 1.2 mM and 2.8 mM of NHS and EDC, respectively [for NHS/EDC 
BNCs]) and pH was adjusted at different values and the absorbance was measured 
(pH was first decreased and then increased in the same tube). Both non-NHS/EDC 
and NHS/EDC conjugates had similar behaviour, with minimal aggregation 
throughout the pH range (pH = 1 - 11) tested. This result was dramatically different 
from the result obtained for naked AuNP-MUA particles and thus pH aggregation was 
a further proof of conjugation (figures 24, 25, 26, 27).     
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4.6   PfHsp70 expression 
4.6.1 Transformation of pQE30/PfHsp70 into 5RVHWWD%OXHFHOOV 
Successful transformation of the pQE30/PfHsp70 plasmid into 5RVHWWD%OXH cells 
was confirmed by the presence of colonies of transformed cells onto LB agar plates 
containing both ampicillin and chloramphenicol. Positive control (transforming a ³WHVW
SODVPLG´ with ampicillin resistance instead of pQE30/PfHsp70) but not negative 
control (autoclaved water instead of plasmid added) showed colonies of transformed 
cells. Figure 28 shows colonies on LB plates (containing both ampicillin and 
chloramphenicol) representing RosettaBluHFHOOVWUDQVIRUPHGZLWKHLWKHU
pQE30/PfHsp70 or positive control plasmid but no colonies seen for untransformed 
negative control.  
 
4.6.2 Expression of PfHsp70 under different induction conditions 
For PfHsp70 expression, a 50 mL pre-inoculum was prepared using a colony of 
5RVHWWD%OXHFHOOVWUDQVIRUPHGZLWKS4(PfHsp70, from which three 250 mL 
cultures was fermented. Samples were withdrawn during bacterial culture and O.D600 
was measured. O.D values increased indicating bacterial growth till O.D value 
ranging from 0.5 - 0.6. At that time point, the three cultures were exposed to different 
induction and harvesting conditions (³QR,37*´³,37*KU´DQG³,37*RYHUQLJKW´; 
see 3.6.2). Figure 29 shows a curve of O.D600 against time for the different induction 
conditions. After harvesting, SDS-PAGE and Western blot analysis were performed 
for pellets after resuspension in lysis buffer for the different induction conditions 
(figure 30). SDS-PAGE was performed to determine the presence of PfHsp70 in the 
resuspended pellet before purification and to compare between the different induction 
conditions. Western blot analysis was performed to confirm SDS-PAGE result and to 
determine the presence of truncation and degradation products within the impure 
bands. Since harvesting after 2 hrs led to low yield it was not practically feasible to 
XVHWKLVLQGXFWLRQSDWWHUQLQWKHIROORZLQJVFDOHXSH[SHULPHQW³,37*RYHUQLJKW´
culture seemed to produce slightly more pure PfHsp70 WKDQ³QR,37*´FXOWXUH7KLV
was concluded as the ratio of the intensity of the PfHsp70 protein band (75 kDa) to 
other lower bands (protein impurities or degradation and truncation products of 
Pf+VSZDVKLJKHUIRU³,37*RYHUQLJKW´ compared to ³QR,37*´, as shown by 
SDS-PAGE (figure 30). Thus in the following scale up procedure, cultures were 
induced with IPTG and harvesting was done the next day. Western blot analysis 
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showed that within the impure bands appearing on SDS-PAGE, two bands bind to 
2E6 antibody (at ca. 35 kDa and 50 kDa), originating from possible degradation or 
truncation products of PfHsp70  (figure 30). Figure 31 shows SDS-PAGE as well as 
Western blot analysis of transformed and non-transformed 5RVHWWD%OXH cells. As 
seen on SDS-PAGE, there was a band in the non-transformed cells very close to 
PfHsp70 band (present in transformed cells) that was suggested to be DnaK (Hsp70 of 
E. coliH[SUHVVHGE\5RVHWWD%OXH cells)39. Western blot analysis gave a much 
clearer result where a band was seen at 75 kDa (accompanied by bands of possible 
degradation or truncation products at ca. 35 kDa and 50 kDa) for transformed cells 
but no bands for non-transformed cells (figure 31).  
 
4.7   Purification of PfHsp70 using Ni-NTA column 
After cell harvesting, resuspended pellet was homogenised and lysed by French-press 
and purified using Ni-NTA agarose column. Samples before and after purification by 
Ni-NTA column together with washes and flow through were all run on 10% SDS-
PAGE (fig. 32). The sample that eluted from the Ni-NTA column still contained 
impurities (bands at molecular weights different from the 75 kDa) including bands 
from the possible degradation or truncation products at ca. 30 - 35 kDa and 45 - 50 
kDa. The bands from impurities are nevertheless less intense (less amount) than the 
band corresponding to PfHsp70. The second intense band was a band at 30 - 35 kDa 
that was verified by Western blot analysis before to be a degradation or truncation 
product of PfHsp70. Although being only partially purified, the protein was labelled 
with Cy3B. This is because PfHsp70 comprises the highest amount and that the other 
strong band is the degradation or truncation product that can still bind to 2E6 
(according to Western blot) and thus is suitable for the fluorescence quenching 
competitive assay. Further purification of this partially purified protein, using a 
second purification method was suggested, but was not followed since the yield 
would have been dramatically affected. Thus we decided to continue with the partially 
purified sample. The total concentration of PfHsp70 was then determined by BCA to 
be 1.74 mg/mL.  
    
4.8   Labelling of PfHsp70 with Cy3B 
The partially purified PfHsp70 was labelled with Cy3B. The easiest proof of labelling 
is the fact that labelled PfHsp70 is more than 75 kDa and thus does not pass with the 
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filtrate during Centricon washing (membrane cut-off: 30 kDa). However, free dye can 
easily pass since it is very small in size (mwt 771.8). Thus the presence of pink color 
in the solution retained in the Centricon is an indication of labelling. An additional 
proof of labelling, is the shift in the maximum absorbance spectra seen after 
conjugation from 559 nm for free Cy3B to 565 nm after labelling (figure 33). Also a 
peak at 280 nm corresponding to PfHsp70 protein can be observed in conjugated and 
not in free Cy3B, as expected (fig. 33). 
   
4.9   Chip Assay 
For proof-of-concept of the competitive chip assay, a drop of partially purified 
PfHsp70 (see section 3.7) was immobilized on one side of a nitrocellulose sheet and 
non-WUDQVIRUPHG5RVHWWD%OXH cells (resuspended pellet; see 3.6.2) were 
immobilized on the other end. After drying and blocking the nitrocellulose strips, 
normalized NHS/EDC and non-NHS/EDC conjugates (2 nM AuNP-MUA; molar 
ratio = 70; 1.2 mM and 2.8 mM of NHS and EDC, respectively [for NHS/EDC 
BNCs]; blocked with BSA) pre-incubation with either buffer (blank) or with excess 
pure PfHsp70 (positive) were added to the nitrocellulose strips (section: 3.9). Since 
the binding sites of 2E6 antibody will be partially/fully saturated in case of positive 
samples (during pre-incubation), 2E6 will not easily bind to immobilized PfHsp70 
and thus no red color should be seen. However, in blank samples many 2E6 binding 
sites will be exposed, 2E6 will easily bind to immobilized PfHsp70 and consequently 
a red color should be observed (figure 34). As seen in figures 35 and 36, blank 
samples in case of non-NHS/EDC and NHS/EDC gave a red color while positive 
samples gave no color. Importantly, NHS/EDC BNCs were found to be less active 
since the intensity of the red color on the strip of the blank sample of NHS/EDC 
BNCs was faint as compared to that of blank sample of non-NHS/EDC conjugates. 
Thus for the fluorescence quenching competitive assay, non-NHS/EDC conjugates 
were used. Both NHS/EDC and non-NHS/EDC conjugates were specific since the 
BNCs did not bind to the drop having non-transformed bacterial culture (full of non-
target proteins) but only to the drop of the partially purified PfHsp70.   
 
4.10  Fluorescence quenching competitive assay 
As a proof-of-concept for developing a fluorescence quenching competitive assay for 
the quantification of PfHsp70, different concentrations of AuNP-MUA particles (0 - 
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2.75nM) were added to determine their quenching effect over Cy3B-labelled PfHsp70 
diluted in buffer (0.1 M sodium borate pH = 8.3; 150 mM NaCl). A linear relation of 
fluorescence quenching was achieved in the concentration range from 0 to 0.825 nM 
of AuNP-MUA (figure 37). 
 
Proof-of-concept for the fluorescence quenching competitive assay for the 
detection of PfHsp70 was then established (principle explained in 3.10). As seen in 
figure 38, positive samples gave a higher fluorescence intensity value than blank in 
concentrations higher than 87 ng/mL (PfHsp70). However for lower concentrations, 
the difference between positives and blank was less than 3X standard deviation (0.67). 
Thus 87 ng/mL (1.16 pM) was taken as the limit of detection in this study. In figure 
38C, fluorescence enhancement (%) was plotted against the concentration of PfHsp70 
in positive samples. Fluorescence enhancement was calculated as follows (equation 
3):  
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where FI is the fluorescence intensity; average buffer fluorescence intensity value is 
the average fluorescence emission value of the borate buffer alone at 574 nm. 
 
 
(3) 
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CHAPTER 5. DISCUSSION 
In this study, two prototype AuNP-based immunoassays for the detection of PfHsp70 
antigen were developed. Production and purification of anti-PfHsp70 monoclonal 
antibody (2E6) were performed and specificity for Hsp70 in mouse blood and human 
blood culture was determined. 2E6 antibodies were conjugated to AuNPs in the 
presence and absence of NHS/EDC cross-linkers. Characterization of BNCs was 
performed and assessment of BNC stability was then done. PfHsp70 was expressed 
from E. Coli system, purified using Ni-NTA agarose and labelled with Cy3B. Finally, 
a  prototype dipstick chip assay and a prototype fluorescence quenching competitive 
immunoassay for the detection of PfHsp70 were developed.  
 
5.1   Purification and specificity of 2E6 antibody 
2E6 antibody was purified from hybridoma culture in two steps. The first step is 
purification using Protein G Sepharose 4 Fast Flow column and the second using PD 
SpinTrap G-25 disposable columns. Protein G is a group G Streptococcal bacterial 
protein that has high affinity for IgG antibodies41. Protein G columns were chosen 
rather than Protein A since protein G binds to a wider range of IgGs from eukaryotic 
species as well as to different IgG subtypes 41 (table 1; appendix). The monoclonal 
antibody 2E6 was only partially purified using the Protein G Sepharose 4 Fast Flow 
column and the process required further optimization (such as increasing the number 
of washes before elution). Thus it was decided to use the disposable spin columns to 
purify the whole batch of partially purified 2E6. When the two bands of 2E6 obtained 
in the SDS-PAGE were compared with the marker, their molecular weights were ~31 
kDa and ~58 kDa, respectively. Theoretical values for IgG antibody sub-units are 25 
kDa and 50 kDa, respectively. The 25 kDa band corresponds to the light chains of the 
antibody and the 50 kDa band corresponds to the heavy chains of the antibody, that 
were linked together through disulphide linkages (figure 39)63.   
   
To determine the specificity of 2E6 for parasitic Hsp70 and to prove that 
Hsp70 is a diagnostic target for the diagnosis of malaria, Western blot analysis was 
performed. Since P. falciparum human infected blood was not available, P. berghei 
infected and non-infected mice blood were analyzed instead since it was proven 
previously that 2E6 recognizes both PfHsp70 and PbHsp7045. Western blot analysis 
for the detection of PbHsp70 using 2E6 antibody was first performed on plasma and 
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on whole blood of P. berghei infected and non-infected mice blood. Comparison of 
infected and non-infected mice plasma suggests that PbHsp70 is not secreted into 
plasma and thus plasma is not an appropriate specimen for the diagnostic assay. 
However, in the case of whole blood of infected mice, an additional band at about 75 
kDa (corresponding to PbHsp70) was observed when compared to whole blood of 
non-infected mice. However, since several bands were seen in non-infected whole 
blood samples that were very similar to those of non-infected plasma, it was reasoned 
that 2E6 non-specifically binds to other proteins, mainly in plasma, and thus the most 
suitable sample will not be whole blood but instead the detection of PbHsp70 in 
isolated RBCs. Thus another protocol was followed, where RBCs were separated 
from whole blood, washed twice with PBS and then lysed by saponin and the pellet 
after saponin treatment was washed 4 times with PBS44. Saponin causes RBC lysis, 
leading to the release of RBC cytoplasm contents into the lysate (supernatant). 
Plasmodium Hsp70 was proven not to be exported into the RBC cytoplasm; i.e should 
not be detected in cell lysate but instead should be detected in the saponin pellet that 
contains parasitic proteins that are localized within the parasitic membrane44.When 
the saponin pellet of non-infected mice, infected mice and that of non-infected human 
were compared, PbHsp70 was found only in the infected mice saponin pellet, as 
expected. The 2E6 monoclonal antibody did not bind t o non-infected human saponin 
pellet even when the undiluted sample was analyzed.  
 
As a loading control, anti-actin primary and anti-rabbit secondary antibodies 
were added to the lower part of the blotted membrane while the upper part was treated 
with 2E6 primary antibody and anti-mouse secondary antibody (membrane was cut 
above the 50 kDa marker band; section 3.2.3). It was found that even when the actin 
bands were comparable in intensity for both infected and non-infected mice RBC 
saponin pellets (samples normalized; section 4.2.2), the PbHsp70 band was only 
found in the infected blood. After process optimization using mice blood infected 
with P. berghei, a human blood culture infected with P. falciparum was provided. The 
sample was analyzed by Western blot and compared with mice blood infected with P. 
berghei. Although the intensities of the actin bands in both samples were comparable 
(samples normalized), the band representing PfHsp70 had a much higher intensity 
when compared to the band representing PbHsp70, indicating that the 2E6 
monoclonal antibody binds more strongly to PfHsp70 than to PbHsp70.   
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5.2   Synthesis and functionalization of AuNPs and characterization of AuNP-
MUA-2E6 BNCs 
Gold citrate particles were synthesized and functionalized with MUA. MUA allows 
the uniformity of negative charge onto the particles and was reported to reduce the 
aggregation of citrate particles64. Proof of functionalization with MUA was proven 
previously by the simultaneous detection of gold and sulphur using Inductive Coupled 
Plasma (ICP)62. Another peptide functional group (CALNN) was also tested. But 
since MUA particles were prepared in our laboratory, unlike AuNP- CALNN, and 
gave stable conjugates, further studies were performed on AuNP-MUA instead of 
AuNP-CALNN particles.  
 
After functionalization of AuNP with MUA, conjugation with 2E6 was then 
performed by two strategies. The first strategy was conjugation in the absence of 
NHS/EDC cross-linkers, where conjugation occurs mainly through electrostatic forces 
between 2E6 and MUA groups on the surface of AuNPs. The second strategy was 
conjugation in the presence of NHS/EDC cross-linkers allowing the covalent linkage 
between 2E6 and MUA and thus should lead to more stable and robust conjugates. 
EDC is a dehydrating agent that aids the reaction between two compounds, one 
having an amine group (2E6) and the other having a carboxyl group (MUA). This 
occurs by the binding of EDC to a carboxyl group forming an O-acylisourea 
intermediate that can easily react with an amine group on another molecule forming 
an amide bond. However, if EDC is used alone, the intermediate is susceptible to 
hydrolysis to give the free carbonyl group again. Thus NHS is added to stabilize the 
unstable O-acylisourea intermediate by giving a NHS-ester intermediate and thus 
enhancing the EDC coupling (figure 40)65-66.  
 
Monoclonal antibody (2E6) conjugation to AuNP-MUA was verified using 3 
different techniques, namely: UV-visible spectroscopy, agarose gel electrophoresis 
and ȗ-potential analysis. After conjugation, a shift in absorbance peak maximum 
occurred (from 521 nm to 530 nm) due to the change in the local refractive index 
surrounding the AuNPs67. Another proof of conjugation is agarose gel electrophoresis 
where naked AuNP-MUA aggregated in the wells (due to surface charge cancellation 
caused by the running buffer) while AuNP-MUA-2E6 conjugates were protected from 
aggregation and migrated through the gel towards the positive pole (negative 
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particles) according to their size and charge. Gel electrophoresis enabled the choice of 
the optimum concentration of NHS/EDC needed for the covalent linkage of 2E6 to 
AuNP-MUA particles, where high concentrations led to aggregations of the particles 
as seen as a smear on the gel and/or aggregation in the wells; while compact bands 
were seen at lower concentrations (0.6 mM; 1.4 mM and 1.2 mM; 2.8 mM of NHS 
and EDC, respectively; the latter was considered optimum conditions).Gel 
electrophoresis also enabled the comparison between non-NHS/EDC and NHS/EDC 
conjugates, where NHS/EDC ones were found to be slightly more uniform and robust 
(seen as a tighter band). This is expected since the type of bond formed is covalent 
whereas in case of non-NHS/EDC, it is mainly electrostatic attraction. An additional 
proof of conjugation was the use of ȗ-potential measurements. As 2E6 antibody binds 
to the AuNP-MUA surface, the ȗ-potential increases (becomes less negatively 
charged) due to the change in surface properties of the particles53. Stabilization of ȗ-
potential with the increase in 2E6 to AuNP molar ratio corresponds to a stabilization 
of the number of antibodies that bind to the AuNP-MUA. It was proven that 
NHS/EDC allowed a stronger binding between 2E6 and AuNP-MUA, corresponding 
to a seven- fold increase in the binding constant value (KL = 0.161 and KL = 0.023, for 
NHS/EDC and non-NHS/EDC BNCs, respectively). Thus at low 2E6 to AuNP-MUA 
molar ratios, NHS/EDC seems to allow more antibody to bind to AuNP-MUA. 
However, at high 2E6 to AuNP-MUA molar ratios, when no NHS/EDC cross-linking 
agent was present, a higher ȗ-potential plateau value for the non-NHS/EDC samples 
was achieved, indicating that more 2E6 antibody was bound. 
 
To determine the stability of the BNCs against harsh conditions, an equal 
volume of 5M NaCl was added to NHS/EDC and non-NHS/EDC BNCs. NHS/EDC 
conjugates were found to be slightly more stable than non-NHS/EDC conjugates (for 
molar ratios  15) and for both conjugates a molar ratio of 2E6 to AuNP-MUA less 
WKDQFRXOGQ¶WSURWHFWFRQMXJDWHVIURPDJJUHJDWLQJ. It is important to note that 
theoretically the number of antibodies needed to form a monolayer on the surface of 
the AuNP is about 9 according to the following equation68: 
antibodyIgGofareasurfacegrouphead
monolayerformtoantibodiesofNumber
r24S  (4) 
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 where 4ʌU2 is the surface area of the sphere of AuNP; r is the radius of the 
AuNP sphere (8.5 nm); head group surface area of IgG antibody was reported68 to be 
100 nm2. 
 
According to pH aggregation studies, in the pH range of 1 - 11, both 
NHS/EDC and non-NHS/EDC conjugates had similar behavior, where aggregation 
was minimal throughout the different pH values. However, AuNP-MUA alone were 
dramatically aggregated at pH values  4. Thus this result was an additional proof of 
conjugation. To conclude, NHS/EDC conjugates were slightly more uniform and 
stable against NaCl aggregation than non-NHS/EDC conjugates. 
 
5.3   PfHsp70 expression 
Transformation of pQE30/PfHsp70 into Rosetta%OXH cells was performed through 
heat shock. ,Q0DWDPER¶VVWXG\WZRSODVPLGVZHUHWUDQVIRUPHGpQE30/PfHsp70 
and pRIG) into E. coli XLI Blue cells57. pRIG plasmid was transformed into the cells 
as it encodes tRNAs for rare codons to enhance the yield of the full length  protein 
(PfHsp70) and to inhibit the formation of truncation products. However, in our study, 
only pQE30/PfHsp70 ZDVWUDQVIRUPHGLQWRWKHFHOOVEHFDXVH5RVHWWD%OXH cells 
have the ability to express tRNAs for rare codons as they already have pRARE 
plasmid695RVHWWD%OXH cells resist both chloramphenicol (resistance encoded by 
pRARE plasmid) and tetracycline (resistance encoded by genome). Transformed cells 
having the pQE30/PfHsp70 construct (or positive control) can also resist ampicillin. 
Thus colonies on LB plates (having chloramphenicol and ampicillin) indicate 
transformed cells, either having pQE30/PfHsp70 plasmid or the positive control. 
Expression of PfHsp70 from transformed cells was performed under different 
induction conditions and as illustrated before (section: 4.6.2), induction with IPTG 
and harvesting the next day was chosen as the optimum conditions for PfHsp70 
expression. Western blot analysis showed that within the impure bands appearing on 
SDS-PAGE, two bands (at ca. 35 kDa and 50 kDa) that are also intense represent 
either degradation or truncation products of PfHsp70. Importantly, when SDS-PAGE 
of resuspended pellets of non-transformed cells were compared with those of 
transformed ones, the band representing PfHsp70 was only found in transformed 
cells. However, a band in non-transformed cells was very close to that representing 
PfHsp70 which was suggested to be DnaK (Hsp70 of 5RVHWWD%OXH cells). Western 
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blot analysis also showed that 2E6 only recognized Hsp70 in transformed cells 
(PfHsp70) and not in non-transformed cells (DnaK)57.      
 
5.4   Purification and Cy3B-labelling of PfHsp70 
Since expressed PfHsp70 was His-tagged (6x) at the N-terminus, we used Ni-NTA 
column for purification. Nickel has high affinity for histidine and thus proteins with 
His-tag can be separated from other proteins via affinity chromatography using Ni-
NTA agarose70. 3XULILFDWLRQGLGQ¶WJLYHDVLQJOHEDQGRQ6'6-PAGE and the reason 
for this was not clear. Possible explanations are rapid degradation of PfHsp70 and 
some non-specific binding of impurities to the column. However, the impure bands 
were less intense compared to PfHsp70 band (75 kDa) and the second main band (30-
35 kDa) seemed to belong to a degradation or truncation product of PfHsp70 that can 
bind to 2E6 (as proven by Western blot analysis) and thus is useful for the 
fluorescence quenching competitive assay. Thus this partially purified protein was 
labelled with Cy3B as is.  
 
Although FITC has been used in several fluorescence quenching  
immunoassays with AuNPs (see Chapter 1: introduction) and is inexpensive, we 
preferred to use Cy3B instead due to the multiple advantages of Cy3B over FITC71. 
Cyanine dyes in general are less influenced by tryptophan quenching than 
conventional dyes and thus have high signal to noise ratio. Also they are less affected 
by pH changes and are photostable71.  Table 2 (appendix) compares the properties of 
FITC and Cy3B. Cy3B is the backbone-stabilized form of Cy3. Thus due to the rigid 
structure of Cy3B, Cy3B-labelled proteins have 3-folds brighter fluorescence 
compared to proteins labelled with Cy371. Importantly, Mayilo et al.39 reported that 
the sensitivity of the fluorescence quenching competitive assay (the same method 
used in our study) based on Cy3B was more sensitive than that based on Cy3. Thus 
Cy3B was chosen as the labelling dye in our study. 
 
In our study, Cy3B-NHS ester was used that allows the linkage with the 
protein of interest via acylation of amino groups (primary amino groups present at the 
N- terminus and at H-amino group of lysine). The reaction is stopped by adding a large 
amount of free lysine. Cy3B-labelling was proven not only by a shift in peak 
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maximum of absorbance spectrum (from 559 to 565 nm) upon conjugation but also 
simply by the fact that labelled PfHsp70 was not filtered through the 30 kDa 
Centricon during washing. This is because, the free dye can easily pass through a 30 
kDa Centricon due to its small size (mwt 771.8 Da) while labelled PfHsp70 is more 
than 75 kDa and thus cannot pass with the filtrate during washing of the Centricons 
(30 kDa). Molar ratio of Cy3B to PfHsp70 of 2 : 1 was chosen since this was proven 
to be optimum for BSA labelling which is similar in size to PfHsp70 (BSA: about 67 
kDa; PfHsp70: about 75 kDa)39, 72.   
 
5.5   Chip Assay 
Proof-of-concept of the competitive chip assay was established where when AuNP-
MUA-2E6 conjugates (with or without NHS/EDC) were preincubated with buffer (in 
blank), the strip gave a red color and when overloaded with PfHsp70 (positive 
sample), no color was seen (figures 35, 36). Both NHS/EDC and non-NHS/EDC 
conjugates were specific since they only recognized the drop of immobilized PfHsp70 
but not the drop of resuspended pellet of non-transformed RoVHWWD%OXHFHOOV. 
NHS/EDC BNCs were less active than non-NHS/EDC BNCs since the intensity of the 
red color produced on the strips was fainter than that produced by non-NHS/EDC 
conjugates in the blank samples. This may be due to the partial denaturation of 2E6 
antibody by its covalent linkage to the surface of AuNP-MUA particles73.   
5.6   Fluorescence quenching competitive assay 
A linear relation of fluorescence (of Cy3B) quenching was achieved on the addition 
of AuNP-MUA within the concentration range of AuNP-MUA of 0 to 0.825 nM. 
Proof-of-concept for fluorescence quenching competitive assay was established and 
the detection limit was 87 ng/mL (1.16 pM). Further studies are still needed to 
enhance sensitivity and determine the quantitative linear range. As stated previously, 
Mayilo S et al 39 reported using the same method that the LOD and limit of 
quantitation were 0.2 and 0.6 ng/mL, respectively (0.51 and 1.54  pM, respectively) 
and the quantitative linearity range was between 0.5 - 3 ng/mL (1.28 - 7.69 pM, 
respectively).  
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CHAPTER 6. CONCLUSIONS 
6.1   Summary       
The objectives of the current study were achieved with the establishment of proof-of-
concept of two prototype diagnostic assays for malaria based on the detection of P. 
falciparum Hsp70; (i) competitive based chip assay (ii) fluorescence quenching 
competitive assay. 2E6 monoclonal antibody was produced from hybridoma culture 
and specificity of 2E6 for parasitic Hsp70 was proven using Western blot analysis 
where detection of PbHsp70 in saponin pellet of RBCs of P. berghei infected mice 
and PfHsp70 in that of P. falciparum infected human culture was established. 
Recombinant PfHsp70 antigen was expressed using genetically modified E. coli 
5RVHWWD%OXHFHOOV7RLQFUHDVHWKH\LHld and to produce relatively pure PfHsp70, 
induction of the culture was done using IPTG and harvesting was performed the next 
day. Western blot analysis showed that transformed cells, but not non-transformed 
cells, expressed PfHsp70 protein that was recognized by 2E6 antibody. Purification of 
PfHsp70 was carried out using Ni-NTA column and the partially purified protein was 
labelled using Cy3B, for intended usage in the fluorescence quenching competitive 
assay.    
 
Gold citrate nanoparticles were synthesized and functionalized with MUA. 
Conjugation of 2E6 antibody to AuNP-MUA was then performed either through 
electrostatic linkage (in the absence of NHS/EDC) or through covalent amide bond (in 
the presence of NHS/EDC cross linkers). By comparing these conjugates, NHS/EDC 
BNCs were slightly more uniform (as seen using agarose gel electrophoresis) and 
stable against aggregation induced by 5 M NaCl. However, 2E6 antibody activity was 
more preserved in non-NHS/EDC BNCS than in NHS/EDC BNCs as determined 
using prototype competitive chip assay. Proof-of-concept of the prototype competitive 
chip assay and prototype fluorescence quenching competitive assay was proven. The 
prototype fluorescence quenching competitive assay featured a detection limit of 87 
ng/mL (1.16 pM). Analysis of clinical specimens is still to be determined.  
 
6.2   Future plans 
In this study, we have chosen PfHsp70 as the diagnostic target for our two prototype 
competitive assays (chip and fluorescence quenching). However, PfHsp70 has two 
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main drawbacks. The first is that it is conserved between different species and thus 
false positivity is expected to occur if the patient is infected with a disease caused by 
an agent that has an Hsp70 protein that is recognized by 2E612. An example of such 
an agent is Toxoplasma gondii (causes Toxoplasmosis), since TgHsp70 has a 
similarity of 82% with PfHsp70 (this was known by performing a protein blast 
[NCBI] of the sequence of PfHsp70 that binds to 2E6 [365-681 a.a]. It is important to 
note that PbHsp70, which was found to bind to 2E6 by Western blot analysis, has a 
similarity of 83% with PfHsp70. The second drawback is that, as proven by our 
Western blot analysis, neither whole blood or plasma can be used as the direct 
diagnostic specimen for Hsp70 analysis and that RBCs need to be collected, treated 
with saponin and the saponin pellet washed prior to being analyzed by the diagnostic 
assay. This is not practical in field assays (assays performed in endemic countries) 
since it significantly increases the number of analysis steps. However, we used 
PfHsp70 as diagnostic target for proof-of-concept of our assays since both the plasmid 
expressing PfHsp70 antigen as well as the hybridoma culture expressing 2E6 antibody 
were supplied by our collaborators (Prof. Gregory Blatch [Rhodes University, South 
Africa] and Prof. Maria Mota and Dr. Miguel Prudêncio [Instituto de Medicina 
Molecular, Portugal, respectively). Our group is planning to use both two dimensional 
gel electrophoresis and mass spectroscopy to search for new P. falciparum specific 
proteins in infected human plasma to make diagnosis more sensitive, more specific, 
rapid and easy. After selecting the new target, the chip assay will be developed as a 
competitive assay (concept already proven) using non-NHS/EDC BNCs since they 
were proven to be more active than NHS/EDC conjugates. For the fluorescence 
quenching competitive assay, in order to increase the sensitivity of the assay, cubical 
or decahedral shapes instead of spherical particles will also be tested. Such choice of 
non-spherical nanoparticles is related to the fact that the emission fluorescence spectra 
of Cy3B-labelled protein will overlap more fully with absorbance spectra of cubical 74 
or decahedral particles75 than they do with spherical particles (figure 41). This will 
allow better quenching of the AuNPs to the fluorescence emission of Cy3B-labelled 
PfHsp70 and thus should enhance sensitivity. Also determination of the quantitative 
linear range for the fluorescence quenching competitive assay (for the different 
AuNPs shapes) will be determined.      
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CHAPTER 8. LIST OF FIGURES 
 
Figure 1. Malaria life cycle. In mammals (including humans), the life cycle starts 
with a bite of the individual by an infected mosquito. Sporozoites are released from 
the saliva of the mosquito iQWRWKHSDWLHQW¶VEORRGDQGWKHQreach the liver where 
asexual reproduction occurs, leading to the production of merozoites. Infected 
hepatocytes then rupture, leading to the release of merozoites into the blood stream 
and then into red blood cells (RBCs) and starting the erythrocytic cycle. Another 
asexual replication then takes place leading to the production of more merozoites that 
are then released from ruptured RBCs to invade more RBCs. Some of the merozoites 
start to form male and female sexual forms in the blood of the infected patient. During 
the feeding of a female Anopheles mosquito, these sexual forms are taken up by the 
mosquito leading to the formation of the zygote in its midgut. The zygote formed 
matures to generate ookinetes that divide within oocysts to generate thousands of 
sporozoites. Sporozoites then migrate to the salivary gland ready to be injected with 
the next mosquito blood meal. Figure reproduced from 5. 
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Figure 2. Structure of Hsp70-1. Figure modified from 14.  
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Figure 3. Surface Plasmon Resonance of AuNPs. Figure reproduced from
15
. 
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Figure 4. Giemsa stained RBCs of Plasmodium falciparum infected patient 
showing several P. falciparum ring structures. Figure reproduced from 18. 
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Figure 5. Principle of the fluorescence quenching competitive assay for detection 
of PfHsp70. 
 
: AuNP-MUA-2E6  
 
 
                       : PfHsp70 
                       : Cy3B 
          
                                
       Buffer: 0.1 M borate buffer pH = 8.3; 150 mM NaCl. 
Buffer 
Positive  
 Blank  
: Fluorescence Emission 
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Figure 6. BCA protein assay principle. Reproduced from 
43. 
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Figure 7. SDS-PAGE (12.5%) analysis of 2E6 antibody purified using two step 
Protein G affinity chromatography columns.  
- Lane 1. Marker  
- Lane 2. 2E6 containing solution before purification (sample diluted 1 : 15) 
- Lane 3. Protein G Sepharose 4 Fast Flow column purified 2E6 (sample undiluted) 
- Lane 4. PD SpinTrap G-25 columns purified 2E6 (sample undiluted) 
- Arrows show positions of upper (corresponding to heavy chain; about 58 kDa) and 
lower bands (corresponding to light chain; about 31 kDa) of 2E6 antibody. 
- The reason why a single band was seen in lane 2 (impure 2E6) is perhaps due to 
overloading excess proteins that retarded the migration of bands through the gel.    
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Band Migration 
of band 
Dye 
migration 
Rf Log Mwt 
from curve 
Calculated 
Mwt (Da) 
Theoretical 
Mwt (Da) 
Lower 5.6 9.1 0.615 4.49 30,902 25,000 
Upper 2.8 9.1 0.308 4.76 57,543 50,000 
 
Figure 8. Molecular weight values of the two bands of 2E6 (corresponding to 
heavy and light chains) shown on SDS-PAGE, as calculated based on calibration 
curve. A: Calibration curve of Log Molecular weight vs. Rf (ratio of length of 
migration of sample on gel divided by migration of loading dye). B: Calculation of 
practical molecular weight values of the two bands of 2E6 antibody and comparing 
results with theoretical values.   
B 
A 
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Figure 9. Standard curve of BCA test for determining concentration of purified 
2E6 antibody.  
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Figure 10. Western blot analysis of plasma of non-infected mice (A) and of mice 
blood infected with Plasmodium berghei (B) using 2E6 antibody. As seen in the 
figure, no difference can be seen between infected and non-infected plasma. Samples 
are in the following sequence for figures A and B: Lane 1) Undiluted plasma; Lane 2) 
MW markers; Lanes 3-9 Plasma at different dilutions: 3) 1 : 5; 4) 1 : 25; 5) 1 : 125; 6) 
1 : 625; 7) 1 : 3125; 8) 1 : 15625; 9) 1 : 78125.   
- SDS-PAGE: 10% 
- Primary antibody: 2E6 
- Secondary antibody: HRP-labelled anti-mouse antibody 
  
A B 
         1     2    3   4     5    6   7   8   9          1     2    3    4    5   6     7   8   9 
64 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Western blot analysis of whole blood of non-infected mice (A) and of 
mice infected with Plasmodium berghei (B) using 2E6 antibody. This figure shows 
that there is an extra band (lanes 3, 4 and 5) at about 75 kDa in infected (B) but not in 
non-infected whole blood (A). 
- Arrow shows the band of PbHsp70. 
- Samples are in the following sequence for figures A and B: Lane 1) Undiluted 
whole blood; Lane 2) MW markers; Lane 3-9 Whole blood with different 
dilutions: 3) 1 : 5; 4) 1 : 25; 5) 1 : 125; 6) 1 : 625; 7) 1 : 3125; 8) 1 : 15625; 9) 1 : 
78125.               
- SDS-PAGE: 10%. 
- Primary antibody: 2E6. 
- Secondary antibody: HRP-labelled anti-mouse antibody. 
A B 
          1   2      3   4    5     6    7    8    9          1      2     3     4      5      6      7      8      9 
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Figure 12. A: Western blot analysis comparing plasma, saponin supernatant 
(RBC lysate) and saponin pellet of non-infected mice; mice infected with 
Plasmodium berghei; and non-infected human blood, using 2E6 antibody. The 
figure shows that the saponin pellet of treated RBC of infected mice showed the band 
corresponding to PbHsp70. B: Western blot analysis comparing saponin pellet of 
non-infected mice; mice infected with Plasmodium berghei; and non-infected 
human blood, using 2E6 antibody. The figure shows that the saponin pellet of 
treated RBC of infected mice only showed the band corresponding to PbHsp70 but 
this band was not seen for non infected mice and human. C: Western blot analysis 
showing undiluted saponin supernatant and saponin pellet of non-infected 
human blood, using 2E6 antibody. The figure shows that no bands were seen when 
undiluted saponin pellet of non-infected human blood was analyzed. 
- Arrows show the band of PbHsp70. 
- SDS-PAGE: 10%. 
- Primary antibody: 2E6. 
- Secondary antibody: HRP-labelled anti-mouse antibody. 
- P: plasma; PL: saponin pellet; S: saponin supernatant. 
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Figure 13. Western blot analysis of non-infected mice saponin pellet and of mice 
infected with Plasmodium berghei, using actin as loading control. The figure 
shows that the actin band intensities were comparable (lower bands; samples 
normalized) and that the PbHsp70 band was seen in infected mice saponin pellet and 
not in non-infected mice saponin pellet.  
- Arrow shows the band of PbHsp70. 
- SDS-PAGE: 10%. 
- Primary antibody: 2E6. 
- Secondary antibody: HRP-labelled anti-mouse antibody. 
- IM: infected mice saponin pellet; NIM: non-infected mice saponin pellet. 
- Numbers represent dilution. 
NIM    IM 
1:5       1:5 
75 kDa 
40 kDa; 
actin 
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Figure 14. Western blot analysis of saponin pellets of RBCs of mice infected with 
Plasmodium berghei and of human blood culture infected with Plasmodium 
falciparum. This figure shows that the actin band intensities were comparable 
(samples normalized) and that the band corresponding to PfHsp70 was larger than that 
corresponding to PbHsp70 (2E6 recognizes PfHsp70 more than PbHsp70).       
- SDS-PAGE: 10%. 
- Primary antibody: 2E6. 
- Secondary antibody: HRP-labelled anti-mouse antibody. 
- IH: infected human; IM: infected mouse; N: neat (undiluted). 
 
 
 
 
 
 
    
 
 
 
 
IM N     IH N 
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Figure 15. Absorbance spectrum of AuNP-MUA before and after 2E6 
conjugation showing a shift in peak maximum from 521 nm to 530 nm for both 
NHS/EDC and non-NHS/EDC BNCs.  
- Molar ratio of 2E6 to AuNP-MUA for both NHS/EDC and non-NHS/EDC 
conjugates was 100. 
- BNCs: bionanoconjugates. 
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Figure 16. Unstained agarose gel electrophoresis of AuNPs and 
bionanoconjugates (BNCs) prepared with different molar ratios of BSA to 
AuNP-MUA. A: BSA BNCs; B: unconjugated AuNPs alone; C: Rf values 
(distance migrated by sample to total distance till end of gel) vs. molar ratio of 
 100     250     500     1000    2000   3000   4000 
AuNP   AuNP  
MUA   Citrate 
A                                                                           
C 
B                             
D 
 - 
 - 
 - 
 + 
 + 
 + 
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BSA to AuNP-MUA; D: digital photograph showing the appearance of the band 
of a BSA BNC on the agarose gel.  
- BSA bionanoconjugates migrate according to size and charge (fig. 15 A). 
Unconjugated AuNPs were stuck in wells due to charge cancellation and/or 
aggregation caused by running buffer (fig. 15 B). 
- Numbers represent molar ratios of BSA to AuNP-MUA (fig. 15A).  
- Agarose concentration: 1% in 5 mM sodium phosphate buffer (pH = 7) 
- Running buffer: 5 mM sodium phosphate buffer (pH = 7). 
- All bands appeared red in color DVVHHQLQ³'´ however the available camera with 
high resolution was only black and white. 
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Figure 17. Unstained agarose gel electrophoresis of AuNP-MUA-2E6 conjugates 
prepared with different NHS/EDC concentrations showing that 0.6 - 1.2 mM and 
1.4 - 2.8 mM concentration of NHS and EDC, respectively, were found to be 
optimal for cross-linking (compact bands seen). 
- Lane 1. 6 mM and 14 mM of NHS and EDC, respectively. 
- Lane 2. 3 mM and 7 mM of NHS and EDC, respectively. 
- Lane 3. 1.2 mM and 2.8 mM of NHS and EDC, respectively. 
- Lane 4. 0.6 mM and 1.4 mM of NHS and EDC, respectively. 
- The molar ratio of 2E6 to AuNP-MUA was 250. 
-    Agarose concentration: 1% in 5 mM sodium phosphate buffer (pH = 7). 
-    Running buffer: 5 mM sodium phosphate buffer (pH = 7). 
-    All bands appeared red in color, however the available camera with high 
resolution was only black and white. 
1          2                 3       4 
 - 
 + 
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Figure 18. Unstained agarose gel electrophoresis of AuNP-MUA-2E6 conjugates 
(with and without NHS/EDC) prepared with different molar ratios of 2E6 to 
AuNP-MUA. This figure shows that NHS/EDC BNCs are slightly more uniform 
(more compact bands) than non-NHS/EDC BNCs. 
-   Numbers represent molar ratios of 2E6 to AuNP-MUA.  
-   Agarose concentration: 1% in 5 mM sodium phosphate buffer (pH = 7) 
-   Running buffer: 5 mM sodium phosphate buffer (pH = 7). 
-   All bands appeared red in color, however the available camera with high resolution 
was only black and white. 
     5    10     15   20    30    50   70             5     10   15    20    30    50    70    - 
 + 
Non-NHS/EDC BNCs      NHS/EDC BNCs 
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Figure 19. Unstained agarose gel electrophoresis of AuNP-CALNN-2E6 
conjugates prepared with different NHS/EDC concentrations. This figure shows 
that 3 mM and 7 mM concentration of NHS and EDC, respectively, was optimal for 
cross-linking (compact band).   
-   Lane 1: buffer alone  
-   Lane 2:  0.3 mM and 0.7 mM of NHS and EDC, respectively. 
-   Lane 3: 0.6 mM and 1.4 mM of NHS and EDC, respectively. 
-   Lane 4: 1.2 mM and 2.8 mM of NHS and EDC, respectively. 
-   Lane 5: 3 mM and 7 mM of NHS and EDC, respectively. 
-   The molar ratio of 2E6 to AuNP-MUA was 100. 
-   Agarose concentration: 1% in 5 mM sodium phosphate buffer (pH = 7) 
-   Running buffer: 5 mM sodium phosphate buffer (pH = 7) 
-   All bands appeared red in color, however the available camera with high resolution 
was only black and white. 
1           2          3          4                        5  - 
 + 
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Figure 20. ȗ-potential of non-NHS/EDC and NHS/EDC AuNP-MUA-2E6 
bionanoconjugates. This figure shows that NHS/EDC coupling increases the binding 
between 2E6 and AuNP-MUA by about 7 folds for low 2E6/AuNP-MUA molar 
ratios. 
- Zeta-potential measurements were performed in a Zetasizer Nano-ZS from 
Malvern Instruments. A 4 mW He-Ne laser (633 nm) was used with a fixed 173 º 
'/6RUȗ-potential) scattering angle. The software was adjusted as follows: 
material: protein; dispersant: water; temperature: 25oC; equilibration time: 900 
sec; measurement: monomodal; number of measurements: 4; number of runs: 100. 
KL=0.023 
KL=0.161 
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Figure 21. Absorbance spectra of non-NHS/EDC (A) and NHS/EDC (B) AuNP-
MUA-2E6 BNCs after adding an equal volume of 5 M NaCl. This figure shows 
that a molar ratio of 2E6 to AuNP-MUA less than 20 could not protect the BNCs 
(with or without NHS/EDC) from NaCl-induced aggregation as shown by shifts in 
peak maxima. 
- BNCs: bionanoconjugates; R: molar ratio of 2E6 to AuNP-MUA. 
A 
B 
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Figure 22. Ratio of absorbance of aggregated (agg.) forms (659 nm) to non-
aggregated (non-agg.) forms (530 nm) after adding an equal volume of 5 M NaCl 
vs. the molar ratio of 2E6 to AuNP-MUA of BNCs prepared with and without 
NHS/EDC. This figure shows that a molar ratio of 2E6 to AuNP-MUA less than 20 
could not protect the BNCs (with or without NHS/EDC) from NaCl-induced 
aggregation. Also NHS/EDC BNCs seemed to be slightly more stable against NaCl-
induced aggregation compared to non-NHS/EDC BNCs (value of agg./non-agg. was 
less for molar ratios  15 in case of NHS/EDC BNCs).  
- BNCs: bionanoconjugates.
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Figure 23. A: Visible absorbance spectra of 1nM AuNP-MUA at different pH 
values. B: Ratio of absorbance of aggregated forms of 1nM AuNP-MUA (666 
nm) to that of non-aggregated forms (523 nm) at different pH values. This figure 
shows that AuNP-08$DJJUHJDWHDWS+YDOXHV     
A 
B 
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Figure 24. Absorbance spectra of AuNP-MUA-2E6 BNCs prepared in the 
presence of NHS/EDC at different pH values. A. pH was decreased using 0.1 M 
HCl (in the same tube); B: pH was increased using 0.1 M NaOH (in the same 
tube). NHS/EDC BNCs show minimal aggregation at pH values ranging from 1 - 11. 
This is a proof of conjugation since BNCs behave differently from unconjugated 
AuNP-MUA (fig. 23 A).  
- Molar ratio of 2E6 to AuNP-MUA for both NHS/EDC and non-NHS/EDC 
conjugates was 70. 
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Figure 25. pH aggregation study of AuNP-MUA-2E6 BNCs prepared in the 
presence of NHS/EDC showing ratio of absorbance of aggregated forms of BNCs 
to that of non-aggregated forms at different pH values. A: pH was decreased 
using 0.1 M HCl in the same tube (aggregated form 532 nm; non aggregated 
form: 523 nm); B: pH was increased using 0.1 M NaOH in the same tube 
(aggregated form 562 nm; non aggregated form: 528 nm). This figure shows that 
NHS/EDC BNCs show minimal aggregation at pH values ranging from 1 - 11. This is 
a proof of conjugation since BNCs behave differently from unconjugated AuNP-
MUA (fig. 23 B).  
- Molar ratio of 2E6 to AuNP-MUA for both NHS/EDC and non-NHS/EDC 
conjugates was 70. 
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Figure 26. Absorbance spectra of AuNP-MUA-2E6 BNCs prepared in the 
absence of NHS/EDC at different pH values. A. pH was decreased using 0.1 M 
HCl (in the same tube); B: pH was increased using 0.1 M NaOH (in the same 
tube). Non-NHS/EDC BNCs show minimal aggregation at pH values ranging from 1 
- 11. This is a proof of conjugation since BNCs behave differently from unconjugated 
AuNP-MUA (fig. 23 A).  
- Molar ratio of 2E6 to AuNP-MUA for both NHS/EDC and non-NHS/EDC 
conjugates was 70. 
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Figure 27. pH aggregation study of AuNP-MUA-2E6 BNCs prepared in the 
absence of NHS/EDC showing ratio of absorbance of aggregated forms of BNCs 
to that of non-aggregated forms at different pH values. A: pH was decreased 
using 0.1 M HCl in the same tube (aggregated form 531 nm; non-aggregated 
form: 525 nm); B: pH was increased using 0.1 M NaOH in the same tube 
(aggregated form 562 nm; non-aggregated form: 528 nm). Non-NHS/EDC BNCs 
show minimal aggregation at pH values ranging from 1 - 11. This is a proof of 
conjugation since BNCs behave differently from unconjugated AuNP-MUA (fig. 23 
B).  
- Molar ratio of 2E6 to AuNP-MUA for both NHS/EDC and non-NHS/EDC 
conjugates was 70. 
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Figure 28. LB agar plates having ampicillin and chloramphenicol showing 
5RVHWWD%OXHtransformed cells. A. 5RVHWWD%OXH cells transformed with 
pQE30/PfHsp70 plasmid. B: Negative control prepared with autoclaved water 
instead of plasmid; C: Positive control ³7HVW3ODVPLG´VXSSOLHGE\
manufacturer with cells). 
A 
B 
C 
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Figure 29. Bacterial growth curve showing optical density (O.D600nm) vs time 
under different induction conditions. This figure proves the growth of 
5RVHWWD%OXHFHOOVRYHUWLPH%DFWHULDOJURZWKWLOO2'YDOXHVUDQJLQJIURP - 0.6 
was performed after which cultures were either induced using IPTG (and harvesting 
performed after 2 hrs or the next day) or not induced and harvested the next day.    
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75 kDa 
Figure 30 A. SDS-PAGE (10%) analysis of pellets after resuspension in lysis 
buffer of cultures under different induction conditions. 
- To prevent sample overloading, neat (undiluted) samples for ³,37*KU´DQG
³,37*29´ZHUHSUHSDUHGE\GLOXWLQJLQO\VLVEXIIHUE\DQG
UHVSHFWLYHO\7KHVHZHUHQDPHGQHDWVDPSOHV+RZHYHU³QR,37*´QHDWVROXWLRQ
was used as is without diluting. Then 1 : 2 and 1 : 4 dilutions were performed 
using lysis buffer from these neat solutions. 
- Arrow shows the band of PfHsp70. 
- 2: 2 hrs; OV/N: overnight; W/O: without.  
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Figure 30 B. Western blot analysis of pellets after resuspension in lysis buffer of 
cultures under different induction conditions.  
- Note to Fig. 29: to prevent sample overloading, neat (undiluted) samples for 
³,37* KU´DQG³,37*29´ZHUHSUHSDUHGE\GLOXWLQJLQO\VLVEXIIHUE\ : 2.5 
and 1 : UHVSHFWLYHO\7KHVHZHUHQDPHGQHDWVDPSOHV+RZHYHU³QR,37*´
neat solution was used as is without diluting. Then 1 : 2 and 1 : 4 dilutions were 
performed using lysis buffer from these neat solutions. 
- Arrows show the band of PfHsp70. 
- Primary antibody: 2E6. 
- Secondary antibody: HRP-labelled anti-mouse antibody. 
- 2: 2 hrs; OV/N: overnight; W/O: without. 
B 
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Figure 31. SDS-PAGE (10%) and Western blot analysis of pellets after 
resuspension in lysis buffer of transformed and non-transformed 5RVHWWD%OXH
cells. A: Commasie-blue stained SDS-PAGE. B: Western blot analysis. This 
figure shows that PfHsp70 band (at 75 kDa) was seen only in transformed and not in 
non-transformed cells (negative control). There was however a band in non-
transformed cell lane very close to PfHsp70 band (found in transformed cells at 75 
kDa) that was suggested to be DnaK (Hsp70 of E. coli). Western blot analysis showed 
that 2E6 recognizes PfHsp70 (75 kDa) but not DnaK. In transformed cells, two bands 
(ca. 35 kDa and 50 kDa) were also seen suggested to be possible degradation or 
truncation products of PfHsp70.  
- Arrows show the band of PfHsp70. 
- To prevent sample overloading, transformed cell pellet was diluted 1 : 1.7. Non-
transformed cell pellet was diluted 1 : 2. 
- Transf: 7UDQVIRUPHG7UDQVIRUPHGFHOOVDUHWKH³,37*RYHUQLJKW´VDPSOH 
- SDS-PAGE: 10%. 
- Primary antibody: 2E6. 
- Secondary antibody: HRP-labelled anti-mouse antibody. 
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Figure 32. SDS-PAGE (10%) analysis of bacterial culture containing PfHsp70 
before and after Ni-NTA purification. Lane 1) Marker; 2) sample after French-
press and before loading on column (1 : 5); 3) flow through (1 : 5); 4) wash; 5) 
concentrated eluate (1 : 1.5)   
- Arrow shows the band of PfHsp70. 
- Although the eluted PfHsp70 (lane 5) was only partially pure, the protein was 
labelled with Cy3B as is. This is because the intensity of the PfHsp70 band was 
much higher than the impurities and that the second intense band at ca. 30-35 kDa 
was a probable degradation or truncation product of PfHsp70 that can bind to 2E6 
(verified by Western blot analysis) and is useful for the fluorescence quenching 
competitive assay.  
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Figure 33. Absorbance spectra of free Cy3B (red trace) and of Cy3B-labelled 
PfHsp70 (blue trace). Shift in peak maximum occurred from 559 nm to 565 nm upon 
labelling. An additional band at 280 nm was found in case of Cy3B-labelled PfHsp70 
but not in case of free Cy3B. 
- Molar ratio of Cy3B to PfHsp70 was 2 : 1. 
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Figure 34. Chip competitive assay principle. 
  
 
                           : Non-transformed 5RVHWWD%OXHFHOOV (negative control)  
                                   
                     : red color produced on chip assay  
 
Positive 
Sample 
Blank 
Borate 
buffer 
  : AuNP-MUA-2E6 
: PfHsp70 
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Figure 35. Prototype chip assay utilizing non-NHS/EDC bionanoconjugates. 
Non-NHS/EDC conjugates pre-incubated with either buffer (blank) or an 
overload of PfHsp70 (positive) were added to nitrocellulose strips having two 
spots of immobilized proteins: on the left, purified PfHsp70 was immobilized 
while on the right non-WUDQVIRUPHG5RVHWWD%OXHFHOOV were immobilized. A. 
Blank sample; B: Positive sample.  
- This figure shows that no red color was produced for the negative control. Since 
the chip assay is a competitive assay, a red color on immobilized PfHsp70 was 
produced in blank sample (binding sites of 2E6 are free) but not for positive 
sample.  
- NT: non-transformed.  
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Figure 36. Prototype chip assay utilizing NHS/EDC bionanoconjugates. 
NHS/EDC conjugates pre-incubated with either buffer (blank) or an overload of 
PfHsp70 (positive) were added to nitrocellulose strips having two spots of 
immobilized proteins: on the right, purified PfHsp70 was immobilized while on 
the left non-WUDQVIRUPHG5RVHWWD%OXHFHlls were immobilized. A. Blank 
sample; B: Positive sample. This figure shows that no red color was produced for the 
negative control. Since the chip assay is a competitive assay, a red color on 
immobilized PfHsp70 was produced in blank sample (binding sites of 2E6 are free) 
but not for positive sample. Red color intensity on blank was found to be fainter 
compared to non-NHS/EDC BNCs (fig. 34). 
- NT: non-transformed.  
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Figure 37. Quenching effect of AuNP-MUA on fluorescence emission of Cy3B-
labelled PfHsp70. A: Fluorescence spectra of Cy3B-labelled PfHsp70 after 
adding different concentrations of AuNP-MUA. B: Fluorescence intensity at the 
peak maximum (after subtraction of the average buffer value) vs. the final 
AuNP-MUA concentrations. Linearity was achieved from concentration of AuNP-
MUA ranging from 0 - 0.825 nM. 
- Average buffer fluorescence intensity value is the average fluorescence emission 
value of the borate buffer alone at 572 nm; Excitation wavelength used was 480 
nm. 
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Figure 38. Fluorescence quenching competitive assay. Positive samples with 
different PfHsp70 concentrations (8.7 µg/mL; 870 ng/mL; 87 ng/mL; 8.7 ng/mL; 
870 pg/mL) were analyzed by adding AuNP-MUA-2E6 (pre-incubated with 
different PfHsp70 concentrations) to Cy3B-labelled PfHsp70 and measuring 
fluorescence emission immediately. A: Fluorescence spectra of blank and positive 
samples. B: Fluorescence intensity at peak maximum for blank and positive 
samples. C: Fluorescence enhancement (%) for the 5 positive samples.  
- Fluorescence enhancement was calculated as follows: 
1001(%) u¸¸¹
·
¨¨©
§

 
valueFIbufferaveragevalueFISample
valueFIbufferaveragevalueFIBlank
tenhancemenceFluorescen
 
FI: fluorescence intensity; average buffer fluorescence intensity value is the average 
fluorescence emission value of the borate buffer alone at 574 nm; Excitation 
wavelength: 480 nm. 
C 
95 
 
 
 
 
 
 
 
 
 
 
Figure 39. Structure of IgG antibody. Figure modified from
63.  
50 kDa 
25 kDa 
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Figure 40. Principle of NHS/EDC cross-linking.  EDC is a dehydrating agent that 
links a carboxyl-containing compound (such as MUA) to an amine-containing 
compound (such as 2E6) through the formation of an O-acylisourea intermediate. 
Although O-acylisourea intermediate is reactive with amine groups and gives an 
amide bond, it is susceptible to hydrolysis to give the free carbonyl group again. If 
Sulfo-NHS is added in the reaction media, it reacts with the unstable O-acylisourea 
intermediate forming an NHS-ester intermediate that is more stable and is also 
reactive with amine groups. Thus NHS enhances the cross-linking efficacy of EDC. 
Figure modified from 65-66. 
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Figure 41. Fluorescence emission band of the Cy3B-labelled antigen overlaps 
with the absorbance spectra of antibody-conjugated AuNPs (different AuNP 
shapes: spherical, cubical and decahedral) 74-75. Antibody-conjugated cubical and 
decahedral AuNPs absorbance spectra overlap better with the fluorescence emission 
spectra of Cy3B-labelled antigen compared to spherical particles.   
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CHAPTER 9. LIST OF TABLES 
Table 1. The advantages and disadvantages of the different diagnostic assays for 
malaria. Table modified from
3  
Method Type Sensitivity Advantages Disadvantages 
Light 
microscopy 
Direct x 50 - 100 
parasites/µL 
x Can reach 10 
parasites/µL in 
expert centres 
x Standard method 
x Differentiates 
Plasmodium spp 
x Determines 
parasitemia level 
x Low direct cost 
x Labour intensive 
x Requires technical 
expertise 
x Low turn-around 
time 
Rapid 
diagnostic 
tests (RDTs) 
Direct 100 parasites/µL x Simple 
x Easy 
x Rapid  
x Requires minimal 
infrastructure and 
expertise 
x Cost effective 
x Affected by field 
conditions such as 
heat and humidity 
x False positives 
with rheumatoid 
factor 
Polymerase 
chain 
reaction 
(PCR) 
Direct 1 - 5 
parasites/µL 
x Sensitive  
x Rapid 
x High throughput 
analysis 
x Method standardized 
x Differentiates 
Plasmodium spp 
x High capital and 
operating costs 
x Advanced 
infrastructure 
needed 
x Trained personnel 
required 
Flow 
cytometry 
Indirect Not applicable x Uses standard 
hematology analyzers 
x Especially potentially 
useful for diagnosing 
clinically un- 
suspected imported 
malaria  
x Expensive  
x Diagnosis should 
be confirmed via 
other methods 
Laser 
desorption 
mass 
spectroscopy 
Indirect 10 parasites/µL x Rapid 
x Easy 
 
x Very expensive 
equipment 
x Not availble in 
routine labs 
x Until now cannot 
differentiate 
between the 
different P. sp 
¶: Sensitivity ranges from 49 - 98%. Sensitivity differs between semi-immune and non-
immune populations. 
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Table 2. Composition of SDS-PAGE. 
Resolving gel 
 
 
 
 
Stacking gel 
 
Reagent Volume added for a 4%gel 
Water 1.525 mL 
Acrylamide 30% 0.325 mL 
0.5 M tris pH = 6.8 0.625 mL 
10% sodium dodecyl sulfate 
[SDS] 
25 µL 
10% ammonium persulfate 
[APS]  
12.5 µL 
Tetramethylethylenediamine 
[TEMED]  
2.5 µL 
Reagent Volume added for a 10% 
gel 
Volume added for a 12.5% 
gel 
Water 2.01 mL 1.65 mL 
Acrylamide 30% 1.665 mL  2.08  mL 
1.5 M tris pH = 8.8 1.25 mL 1.25 mL 
10% sodium dodecyl sulfate 
[SDS] 
100 µL 100 µL 
10% ammonium persulfate 
[APS]  
15 µL 15 µL 
Tetramethylethylenediamine 
[TEMED]  
10 µL 15 µL 
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Table 3. Volume/concentration  of AuNP-MUA added to quench fluorescence 
emitted by Cy3B-labelled PfHsp70. 
 
Final concentration of 
AuNP-MUA (nM) 
Volume of AuNP-MUA 
(11.03nM) added (µL)  
Milli-Q water (µL) 
0 0 200 
0.275 10 190 
0.41 15 185 
0.55 20 180 
0.61875 22.5 177.5 
0.6875 25 175 
0.825 30 170 
0.9625 35 165 
1.375 50 150 
2.75 100 100 
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Table 4. Determination of the concentration of 2E6 antibody using BCA 
µL of 2E6 
added¶  
Absorbance 
(562 nm) 
(Absorbance - 
intersection with y 
axis) ¶¶ /gradient 
Conc. (mg/mL) 
¶¶¶ by dividing 
DF  
Average 
conc. 
(mg/mL) 
Average 
conc. 
(µM) 
10 0.4309 15.9 3.18 by dividing 
by DF (5) 
3.13  20.9 
10 0.4507 16.8 3.36 by dividing 
by DF (5) 
20 0.7338 29.8 2.98 by dividing 
by DF (10) 
20 0.7394 30 3 by dividing by 
DF (10) 
30 0.9382 Off limit (outside 
standard curve) 
NA NA NA 
30 0.9763 Off limit NA NA NA 
 
¶:  diluted 1 : 2 in sodium phosphate buffer 
¶ ¶: of standard curve 
¶¶¶:  after adjusting dilution factor 
Conc: concentration; DF: dilution factor; NA: not applicable 
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CHAPTER 10. APPENDIX 
Table 1. Comparison between antibody binding to protein A and G. Table 
reproduced from 42. 
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Table 2. Comparison between FITC and Cy3B. Table reproduced from 
71. 
 
 
   
